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ABSTRACT 
There is an increasing body of evidence indicating an important role for the bioactive signalling 
lipid S1P (sphingosine 1-phosphate) in cancer. Sphingosine kinase-1 (SPHK1), one of the 
enzymes responsible for the synthesis of S1P, is reported to be overexpressed in many cancer 
types; in many cases correlating with increased tumour grade and reduced patient survival. 
However, the expression of SPHK1, and how it might contribute to lymphomagenesis, has not 
previously been explored in diffuse large B-cell lymphoma (DLBCL). 
In chapter 3, I show that SPHK1 overexpression in DLBCL correlates with the expression of 
known tumour-angiogenic genes. I also describe the characterisation of human umbilical vein 
endothelial cells (HUVEC) as an in vitro model with which to study the impact of S1P on the 
endothelial cell transcriptome and to explore the extent to which these changes can be 
observed in primary DLBCL. 
In chapter 4, I explore the effects of S1P on the transcription of endothelial cells with a focus 
on genes associated with leukocyte recruitment. I confirm the S1P-induced upregulation of 
chemokines and adhesion molecules in HUVEC and show that SPHK1 expression correlates 
with the expression of stromal cell gene signatures in primary DLBCL.  
Finally, in chapter 5, I show that I can inhibit S1P-induced signalling in HUVEC with 
Sphingomab, a monoclonal antibody against S1P. Additionally, I validate the A20 syngeneic 
model of lymphoma as a relevant system which could be used to study the potential 
therapeutic targeting of SPHK1-S1P signalling in DLBCL.
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CHAPTER ONE 
INTRODUCTION 
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1.1 Diffuse large B cell lymphoma  
1.1.1 Epidemiology 
Non-Hodgkin lymphomas (NHL) are malignant cellular proliferations which arise from normal 
cells at different stages during the process of B cell development. Diffuse large B cell 
lymphoma (DLBCL) is the most common type of NHL accounting for approximately 30% of 
cases (Project, 1997). Men are slightly more susceptible than woman and the most common 
age of diagnosis is in the late 60s, although the disease can occur at any age (Novelli et al., 
2013, Cancer Research UK, 2013). DLBCL is a highly heterogeneous disease both biologically 
and clinically. The disease can be nodal and/or extranodal and is defined by the World Health 
Organisation (WHO) as, “a diffuse proliferation of large B lymphoid cells whose nuclei are 
equal to or exceeding normal macrophage nuclei or more than twice the size of a normal 
lymphocyte” (Swerdlow, 2008).  
The 2016 revision of the WHO classification of lymphoid neoplasms lists a large number of 
distinct DLBCL subentities, due to the presence of distinct clinical and/or molecular features 
or the propensity to affect distinct anatomical sites (Table 1.1) (Swerdlow et al., 2016). 
However, a significant proportion of DLBCL does not fit into these subgroups, which are 
referred to as DLBCL, not otherwise specified (DLBCL-NOS) (Table 1.1) (Swerdlow et al., 2016). 
Many studies have attempted to subdivide DLBCL-NOS based on molecular differences. Unless 
otherwise stated, DLBCL refers to DLBCL-NOS in this thesis. 
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Table 1.1: 2016 WHO classification of DLBCL. (Swerdlow et al., 2016). *=provisional entity 
Diffuse large B-cell lymphoma, not otherwise specified DLBCL-NOS 
 Germinal centre B-cell type 
 Activated B-cell type 
T-cell/histiocyte-rich large B-cell lymphoma 
Primary DLBCL of the central nervous system (CNS) 
Primary cutaneous DLBCL, leg type 
EBV+ DLBCL, NOS 
DLBCL associated with chronic inflammation 
Primary mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
ALK+ large B-cell lymphoma 
Plasmablastic lymphoma 
Primary effusion lymphoma 
HHV8+ DLBCL, NOS* 
High-grade B-cell lymphoma, with MYC and BCL2 and/or BCL6 rearrangements 
High-grade B-cell lymphoma, NOS 
B-cell lymphoma, unclassifiable, with feature intermediate between DLBCL and classical Hodgkin 
lymphoma 
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1.1.2 Molecular subgroups of DLBCL 
1.1.2.1 Introduction 
Insights into the molecular biology of DLBCL were initially made possible through the use of 
gene expression microarrays, which provide a global profile of mRNA expression. From this, 
histologically indistinguishable molecular subtypes of DLBCL were identified that originate 
from lymphocytes at different developmental stages and use different oncogenic signalling 
pathways (Alizadeh et al., 2000). Before describing these molecular subgroups of DLBCL, it is 
first important to understand the process of normal B cell development and B cell receptor 
(BCR) signalling. 
1.1.2.2 Normal B-cell development 
B lymphocytes are produced in the bone marrow, and B cell development begins with 
rearrangement of the variable regions of the immunoglobulin (Ig) heavy and light chain genes 
to form a functional BCR. This requires double strand DNA breaks which are mediated by the 
recombination activating genes 1, 2 (RAG1 and RAG2) and resolved through the non-
homologous end joining repair process (Fugmann S, 2000). This process is known as VDJ 
recombination and results in a highly diverse repertoire of Ig genes which encode the BCR of 
each B cell (Dudley et al., 2005). Once the BCR is expressed, the B cells leave the bone marrow 
and circulate through blood and lymphoid tissue as mature, naïve B cells where they can 
encounter antigen. 
Upon binding of antigen to the BCR the naïve B cells migrate to secondary lymphoid organs 
such as lymph nodes, Peyer’s patches, tonsils and spleen (MacLennan, 1994, Klein and Dalla-
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Favera, 2008). First, naive B cells migrate to the T-cell-rich zone of secondary lymphoid organs 
where they become fully activated with the help of CD4+ T cells (MacLennan, 1994). These 
activated B cells move to the primary follicle, a structure made up of B cells within a network 
of follicular dendritic cells (FDCs). The B cells then enter the next stage of differentiation and 
start to rapidly proliferate leading to the development of the germinal centre (GC) (Figure 1.1). 
In addition to B cell expansion, a process called somatic hypermutation (SHM) occurs in the 
GC. SHM involves modification of the Ig variable region through random point mutations and 
the introduction of insertions or deletions producing antibodies with a higher affinity for 
antigen (Goossens et al., 1998, Kocks and Rajewsky, 1989, Gearhart and Bogenhagen, 1983) 
(Figure 1.1). These reactions are mediated by the enzyme, activation-induced cytidine 
deaminase (AID) (Muramatsu et al., 2000). Cells with high affinity for antigen are selected  by 
receiving survival signals from T helper cells and FDCs, whereas those with low affinity or 
deleterious mutations undergo apoptosis (Teng and Papavasiliou, 2007) (Figure 1.1). Surviving 
cells can go through another process known as class switch recombination (CSR), resulting in 
replacement of the IgM constant region with IgG, IgA or IgE. This process involves the 
generation of double strand breaks, deletion of unwanted sequence and the subsequent re-
joining of the remaining gene segments within the heavy chain locus. As the variable region is 
not altered, this process does not affect the affinity of the Ig for antigen, but it can now 
interact with different effector molecules (Dudley et al., 2005). CSR also requires AID which is 
regulated by interferon regulatory factor 4 (IRF4) (Klein et al., 2006). IRF4 is induced by antigen 
receptor engagement and CD40 signalling through activation of the nuclear factor-kappaB 
(NF-κB) pathway leading to IRF4 promotor activation (Shaffer, 2009). 
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Figure 1.1: B cell development in the GC. A naïve B cell encounters antigen and then migrates to 
secondary lymphoid follicles. Following T cell stimulation, the B cells undergo clonal expansion and 
somatic hypermutation within the dark zone of the GC. The B cells then migrate to the light zone where 
they are selected for high affinity of their BCR through interaction with T helper cells and follicular 
dendritic cells, escaping the default apoptosis pathway of GC B cells. Selected GC B cells can then 
undergo class switching before differentiating into memory B cells or plasma cells.  
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Histologically, the GC can be divided into the dark zone made up of proliferating B cells 
undergoing SHM referred to as centroblasts, and a light zone in which negative selection and 
CSR of B cells, known as centrocytes, occurs. GC B cells traffic between the dark and light zones 
undergoing multiple rounds of proliferation and selection (Schwickert et al., 2007).  
Cells that successfully emerge from the GC enter the final stage of B cell differentiation where 
they differentiate either into memory cells which provide a rapid response following 
subsequent antigen encounters, or plasma cells, which secrete antibody (Figure 1.1).  
There are many transcription factors which are involved in establishing the GC phenotype such 
as B-cell lymphoma 6 (BCL6), OCT-binding factor 1 (OBF1), SPIB, BTB domain and CNC homolog 
2 (BACH2) and interferon-regulatory factor 8 (IRF8). Of these, BCL6 has been referred to as 
the master transcriptional regulator of centroblasts as it is involved in the repression of 
multiple cellular processes to allow the hypermutation of centroblasts in the dark zone of the 
GC (Basso and Dalla-Favera, 2010, Basso and Dalla-Favera, 2012) (Figure 1.2A). The down 
regulation of BCL6 is required for GC exit  (Shaffer et al., 2000). Signalling through the BCR 
leads to the downregulation of BCL6 expression via mitogen activated protein kinase (MAPK) 
phosphorylation which targets BCL6 for ubiquitin mediated proteosomal degradation (Niu et 
al., 1998). Signalling through CD40 also results in transcriptional silencing of BCL6 as a result 
of NF-κB mediated induction of IRF4, which represses BCL6 expression by binding to its 
promoter region (Saito et al., 2007). The downregulation of BCL6 derepresses B lymphocyte 
induced maturation protein 1 (BLIMP1) which is required for plasma cell development (Turner 
et al., 1994) (Figure 1.2B)
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Figure 1.2: BCL6 in the GC: (A) BCL6 impairs premature B cell activation and differentiation and 
promotes tolerance of DNA damage in the GC centroblasts. (B) Down regulation of BCL6 is required 
for GC exit and differentiation to plasma cells. BCL6 is downregulated by transcriptional repression 
of BCL6 gene by IRF4 due to CD40 stimulation and post transcriptionally by ubiquitination mediated 
BCL6 degradation following BCR stimulation. BCL6 downregulation releases the gene which encodes 
BLIMP1 (PRDM1) from repression which is required for plasma cell differentiation.  
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The distinct modifications of B cell DNA during B cell development such as SHM and CSR are 
essential for the generation of a normal immune response but they also cause DNA damage 
which can lead to the development of lymphomas. 
1.1.2.3 Normal BCR signalling 
The BCR is a multimeric complex comprised of membrane-bound Ig associated with a 
disulphide linked heterodimer of CD79a and CD79b. BCR stimulation induces activation of 
SRC-family kinase (SFK) which phosphorylates immunoreceptor tyrosine-based activation 
motifs (ITAMs) in the cytoplasmic tails of CD79a and CD79b which leads to the recruitment of 
spleen tyrosine kinase (SYC). The signal is then transduced to early effectors of the signalling 
response such as Bruton’s tyrosine kinase (BTK) and phospholipase C-gamma 2 (PLCγ), through 
the adaptor protein B-cell linker (BLNK) (reviewed in: Packard and Cambier, 2013, Rickert, 
2013). BTK phosphorylates PLCγ2 leading to downstream responses including calcium 
signalling, protein kinase C (PKC), NF-κB and extracellular signal-regulated kinase (ERK) 
activation (Figure 1.3). NF-κB activation is due to PKCβ phosphorylation of caspase 
recruitment domain-containing protein 11 (CARD11), leading to the formation of the CBM 
signalling complex (CARD11, BCL10 and MALT1) (reviewed in: Packard and Cambier, 2013, 
Rickert, 2013) (Figure 1.3). The CBM signalling complex activates NF-κB inhibitor kinase (IKK) 
which leads to the phosphorylation and degradation of inhibitor of NF-κB (IκB). IκB masks the 
nuclear localisation signal of p50-p65 NF-κB transcription factors sequestering them in the 
cytoplasm. Following IκB degradation, p50-p65 NF-κB heterodimers accumulate in the nucleus 
and activate their target genes (Figure 1.3). 
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Figure 1.3: Overview of BCR signalling. Activation of the BCR leads to a signalling cascade which 
results in the activation of the NF-κB, mTOR, ERK and NFAT pathways. Signalling is initiated when a 
SRC-family kinase (SFK) phosphorylates ITAM motifs of the BCR subunits CD79A and CD79B which 
leads to the recruitment and activation of SYK. SYK activates the B cell linker (BLNK) adaptor protein, 
which serves as a scaffold for the Bruton’s tyrosine kinase (BTK) mediated phosphorylation of 
phospholipase Cγ2 (PLCγ2). PLCγ2 in turn promotes the influx of calcium ions (Ca
2+
) and activation 
of NFAT pathway; as well as activation of protein kinase Cβ (PKCβ) which initiates ERK signalling. 
Additionally PKCβ phosphorylates CARD11 causing it to recruit BCL10 and MALT1 into a multiprotein 
‘CBM’ complex that activates the NF-κB inhibitor kinase (IKK). Activated IKK leads to the 
phosphorylation and the degradation of inhibitor of NF-κB (IκB) and the nuclear translocation of 
p50-p65 NF-κB heterodimer. In parallel, PI3K is activated by recruitment to the B-cell co-receptor 
CD19 activating the mTOR pathway. A20 is an NF-κB target gene and a negative regulator of the NF-
κB signal.  
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In parallel, phosphoinositide 3-kinase (PI3K) is activated by recruitment to B cell co-receptor 
CD19 leading to the activation of the mechanistic target of rapamycin (mTOR) pathway. The 
activation of these many signalling pathways leads to B cell growth, proliferation and survival 
(reviewed in: Packard and Cambier, 2013, Rickert, 2013).  
1.1.2.4 Cell of origin molecular subtypes 
SHM is detected in DLBCL which suggests that DLBCL arises from B cells which have been 
through a GC reaction. Two molecularly distinct forms of DLBCL have been identified which 
have gene expression profiles indicative of different stages of B cell development. These are 
the germinal centre B-cell like DLBCL (GCB DLBCL) and the activated B-cell like DLBCL (ABC 
DLBCL) (Alizadeh et al., 2000, Rosenwald et al., 2003, Rosenwald et al., 2002). 
GCB DLBCL 
GCB DLBCLs are believed to be derived from GC B cells, as the genes expressed by this sub 
group, such as CD10, LMO2 and the transcriptional repressor BCL6, are highly expressed in 
normal GC B cells (Alizadeh et al., 2000, Rosenwald et al., 2002).   
Many oncogenic signalling pathways are predominantly expressed by only one DLBCL subtype 
(Figure 1.4). A frequent genetic abnormality detected in GCB DLBCL is the t(14:18) 
translocation which deregulates the expression of the anti-apoptotic gene B-cell lymphoma 2 
(BCL2). This translocation has been detected in approximately 45% of GCB DLBCL tumours but 
not in ABC DLBCL (Rosenwald et al., 2002).  
Mutations exclusively found in GCB DLBCL include those affecting the methyltransferase, 
EZH2, detectable in approximately 20% of cases (Morin et al., 2010). EZH2 is the catalytic 
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subunit of the polycomb repressive complex 2 (PRC2) and mutation leads to a gain of function 
and increased methylation of histone 3, resulting in transcriptional silencing of key regulatory 
genes (Beguelin et al., 2013, Sneeringer et al., 2010). EZH2 is a master regulator of the GCB 
cell phenotype and co-operates with BCL6 to mediate lymphoma development in GCB DLBCL 
(Beguelin et al., 2013, Caganova et al., 2013). 
Ten to fifteen percent of GCB DLBCL harbour deletions in the tumour suppressor gene PTEN 
(phosphate and tensin homologue) and a further 15% show amplification of microRNA cluster 
miR-17-92, which suppresses expression of PTEN (Xiao et al., 2008, Lenz et al., 2008c). The loss 
of PTEN expression was detected by immunohistochemistry (IHC) in 55% of GCB DLBCL cases 
compared to only 14% of non-GCB cases (Pfeifer et al., 2013). PTEN deletion results in 
constitutive activation of the PI3K/AKT/mTOR pathway indicating that deregulation of this 
pathway plays an important role in the progression of this subtype. 
ABC DLBCL 
The gene expression profile of the ABC subtype suggests that this type is derived from B cells 
that are in the process of differentiating into plasma cells, as they express genes 
characteristically expressed in plasma cells, such as the transcription factor XBP1 (X-box 
binding protein 1), the master regulator of Ig secretion (Wright et al., 2003, Shaffer et al., 
2004). However, the full plasma cell differentiation is blocked. Inactivating mutations and 
deletions of PRDM1 (PR domain zinc finger protein 1), the gene which encodes BLIMP1 are 
present in approximately on quarter of ABC DLBCL patients (Tam et al., 2006). Furthermore, 
approximately one quarter of ABC DLBCL patients show BCL6 translocations and 26% show 
gain of SPIB, both of which repress the expression of BLIMP1 (Figure 1.4). 
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Figure 1.4: Molecular subtypes of DLBCL: On the basis of gene expression profiling, DLBCL can be 
divided into two molecular subtypes germinal centre B cell like (GCB DLBCL) and activated B cell like 
(ABC DLBCL).  GCB DLBCL are believed to arise from GC B cells, whereas ABC DLBCL from post GC B 
cells in the process of differentiating in to plasma cells. The main oncogenic pathways are listed.  
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A hallmark of ABC DLBCL is the constitutive activation of the NF-κB pathway, which promotes 
cell survival, proliferation and inhibits apoptosis (Davis et al., 2010). Constitutive NF-κB 
activation is largely due to the constitutive formation of the CBM signalling complex which 
leads to IKK activation and degradation of IκB, as described earlier (Figure 1.3). In ABC DLBCL 
the CBM complex is constitutively activated by a number of mechanisms. Approximately 10% 
of ABC DLBCL patients harbour activating mutations of CARD11, whereas those with wildtype 
CARD11 have a chronic active form of BCR signalling  (Lenz et al., 2008a). Mutations in CD79A 
and CD79B genes have been detected in approximately 20% of ABC DLBCL which result in a 
chronic active BCR signal (Davis et al., 2010). The importance of the constitutive activation of 
BCR signalling in ABC DLBCL with wild type CARD11 is highlighted by the dependence of ABC 
DLBCL cell lines upon the activation of SYC, BTK and PKCβ (Davis et al., 2010). 
Inactivation of the NF-κB negative regulator A20 has been detected in around 30% of cases 
which results in loss of inhibition of NF-κB signalling (Figure 1.3). When A20 was reintroduced 
into cell lines carrying biallelic inactivation of the gene it caused apoptosis and cell growth 
arrest, indicating its role as a tumour suppressor (Compagno et al., 2009). The functional 
importance of the NF-κB pathway in ABC DLBCL was shown by Davis et al. (2001) who revealed 
that interference of the NF-κB signalling pathway, using small interfering molecules, was toxic 
to ABC DLBCL cell lines and but not to GCB DLBCL cell lines.  These data strongly support the 
view that chronic active BCR signalling plays a vital role in the pathogenesis of the ABC subtype 
of DLBCL.  
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Mutations in MYD88 have been detected in >30% of ABC DLBCL tumours resulting in the 
upregulation of the NF-κB and Janus-kinase-signal transducer and activator of transcription 
(JAK-STAT) pathways (Ngo et al., 2011).  
BCL2 overexpression is also detected in ABC DLBCL but by mechanisms distinct from those 
observed in GCB DLBCL, including transcriptional upregulation and gene amplification (Lenz et 
al., 2008c). 
1.1.2.5 Identification of GCB DLBCL and ABC DLBCL subtypes 
Due to the ongoing clinical trials to determine whether DLBCL subtype-specific therapies 
should be incorporated into clinical practice (discussed later; Section 1.1.3.4), the 2016 
revision of the WHO classification of lymphoid neoplasms requires the identification of the 
GCB and ABC subtypes of DLBCL (Swerdlow et al., 2016). IHC algorithms are commonly used 
to subdivide DLBCL into subtypes. The most common is the Hans algorithm which uses CD10, 
BCL6 and IRF4 as markers (Hans et al., 2004) (Figure 1.5). Subgroups defined by IHC algorithms 
do not completely correlate with subgroups defined by gene expression profiling (~87% 
correlation, Hans algorithm), partly due to their oversimplification and the poor 
reproducibility of IHC (Meyer et al., 2011). Nevertheless, IHC algorithms will be considered 
acceptable according to the 2016 revision of the WHO classification of lymphoid neoplasms, 
due to the unavailability of gene expression profiling as a routine clinical test (Swerdlow et al., 
2016). Newer methods based on quantification of RNA transcripts using paraffin-embedded 
tissue has proven to provide concordant results with gene expression profiling and capture 
the prognostic impact of cell-of-origin classification (Scott et al., 2014, Scott et al., 2015).
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Figure 1.5: Hans algorithm for the determination of DLBCL subtypes. It is based on the IHC analysis 
of markers CD10, BCL6 and IRF4 (Hans et al,. 2004) 
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These methods are still not accessible to most laboratories, however, may represent a 
promising alternative to IHC algorithms in the future.  
1.1.2.6 Differences in DLBCL survival 
Overall survival is more favourable in those patients with GCB DLBCL compared to ABC DLBCL 
(3-year progression free survival of ~75% vs 40%, p<0.001, respectively) (Rosenwald et al., 
2002, Rosenwald et al., 2003) (Figure 1.6). 
Although the addition of the anti-CD20 antibody rituximab to standard chemotherapy 
combining cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) has greatly 
improved survival in patients, more than 50% of patients with ABC DLBCL will eventually 
succumb to their disease (Lenz et al., 2008b, Coiffier et al., 2002). 
Lenz and colleagues (2008b) profiled gene expression in pre-treatment whole DLBCL biopsy 
specimens to identify gene expression signatures that correlated with differences in survival 
following treatment. They showed that the expression profiles were derived from CD19 
negative non-malignant cells. These ‘stromal signatures’ were variably present in both GCB 
and ABC DLBCL which suggests that these signatures represent biological features of the 
tumour microenvironment which can be acquired during the pathogenesis of both DLBCL 
subtypes. This highlights that survival after treatment is influenced not only by the molecular 
signature of the tumour cells, but also by the composition of the tumour microenvironment. 
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Figure 1.6: Differences in survival between GCB DLBCL and ABC DLBCL: Kaplan-Meier curves of 
survival rates for patients with a molecular diagnosis of the GCB or ABC DLBCL subtype after R-CHOP 
therapy. Patients with GCB DLBCL have a higher probability of progression free survival and overall 
survival than patients with ABC DLBCL (Reproduced from: Wilson, 2013). 
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1.1.2.7 Role of MYC and BCL2 
MYC oncogene rearrangement is a hallmark of Burkitt lymphoma and can also be identified in 
approximately 5-15% of patients with DLBCL. MYC translocation is frequently associated with 
BCL2 and/or BCL6 translocation, referred to as “double-hit” and “triple-hit” lymphomas, 
respectively. Double-hit and triple-hit lymphomas have a very poor prognosis with a median 
overall survival of less than 12 months (Perry et al., 2014, Johnson et al., 2012). They are 
included in the updated 2016 WHO classification in the new category of, “high-grade B-cell 
lymphoma, with MYC and BCL2 and/or BCL6 rearrangements” (Table 1.1) (Swerdlow et al., 
2016).  
Overexpression of MYC protein can be detected by IHC in 30-50% of DLBCL patients and is 
associated with BCL2 expression in 20-35% of cases (Johnson et al., 2012, Green et al., 2012). 
The majority of these tumours do not carry MYC or BLC2 alterations and are referred to as 
“dual-expressers.” “Dual-expressers” have a significantly poorer outcome than patients who 
express only one or neither protein. MYC and BCL2 overexpression can be detected in both 
GCB and ABC DLBCL, although it is more common in ABC DLBCL and is suggested to contribute 
to its inferior survival (Hu et al., 2013).  
1.1.3 Treatment of DLBCL 
1.1.3.1 Prognostic factors 
The identification of distinct molecular subtypes has not yet been translated into changes to 
clinical practice. The International Prognostic Index (IPI), developed prior to the addition of 
rituximab, remains the primary clinical tool to predict outcome of patients with aggressive 
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NHL (Shipp et al., 1993). This is based on the number of negative prognostic factors present 
at diagnosis which include: 
 Age greater than 60 
 Stage III or IV disease 
 Elevated lactate dehydrogenase (LDH) serum level 
 Eastern Cooperative Oncology Group (ECOG) performance status of 2 or more  
 More than one extranodal site of disease 
One point is assigned for each of these factors and the sum of the points classifies patients 
into one of four risk groups with predicted five-year overall survival rates ranging from 26% to 
73% (Shipp et al., 1993). The IPI has been reassessed in patients treated with rituximab-based 
chemotherapy and has been shown to retain its prognostic usefulness (Ziepert et al., 2010). 
However, the IPI fails to identify high-risk patients, as all prognostic IPI categories have a 
higher than 50% chance of cure following treatment with R-CHOP. More recently, an 
enhanced IPI has been proposed using data from the National Comprehensive Cancer Network 
(NCCN-IPI), which was validated within a cohort of patients treated in British Colombia (Zhou 
et al., 2014). The NCCN-IPI uses the same five variables as the IPI, although the categories of 
age and LDH levels are further refined and the specific sites of extra nodal involvement, such 
as bone marrow, CNS, liver/gastrointestinal tract and lung are identified as negative factors, 
rather than the number of sites. The NCCN-IPI was better able to identify a high-risk group 
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with a 5 year overall survival of 33%; however this represented only 8-14% of patients (Zhou 
et al., 2014).  
1.1.3.2 Front line therapy 
Approximately 75% of DLBCL patients present with advanced stage disease which is defined 
as Ann Arbor stages 3 and 4 or stages 1 and 2 with B-symptoms or bulky disease (> 10 cm). 
The CHOP chemotherapy regimen remains the main treatment modality as more intensive 
combinations did not show additional benefit (Fisher  et al., 1993). The addition of rituximab 
to the CHOP backbone dramatically improved outcomes in patients over 60 years of age 
resulting in a 16% improvement to the 10 year overall survival in the first trial (Coiffier et al., 
2010, Coiffier et al., 2002). As a result of this study and of many additional trials, R-CHOP is 
now established as the standard of care (Habermann et al., 2006, Pfreundschuh et al., 2008, 
Pfreundschuh et al., 2006, Sehn et al., 2005). Consolidative radiation therapy following 
chemotherapy is frequently used in an attempt to eradicate potential residual disease. There 
have been no randomised trials assessing the role of this therapy in DLBCL patients in the 
rituximab era. However, retrospective analyses have indicated a benefit for radiation therapy 
following chemotherapy (Dorth et al., 2012, Phan et al., 2010, Held et al., 2014). 
1.1.3.3 Salvage therapy 
Although the standard therapy for many DLBCL patients is curative, approximately 10-15% of 
patients exhibit refractory disease and an additional 20-25% relapse following an initial 
response (Friedberg, 2011). The clinical approach to relapsed/refractory DLBCL includes high-
dose therapy and autologous stem cell transplantation (HD-ASCT). However, due to co 
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morbidities and advanced age only around half of relapsed/refractory DLBCL patients are 
eligible for this intensive treatment. Of those eligible patients only half are sensitive to salvage 
therapy and receive transplant and of those, only half are cured. It was revealed that <10% of 
patients with primary refractory disease following R-CHOP treated at the British Colombia 
Cancer Agency achieved durable remissions with salvage therapies (Hitz et al., 2015).  As a 
result, only very few patients are cured with secondary therapies. Due to the very low 
response rates seen in the salvage setting and the high proportion of patients ineligible for 
such treatments, novel agents are urgently required.  
1.1.3.4 Novel therapies 
Greater insights into the molecular heterogeneity of DLBCL uncovered by gene expression 
profiling have revealed unique therapeutic targets that have translated into the developments 
of novel agents. 
Therapies targeting NF-KB and BCR signalling 
Due to the constitutive activation of the NF-κB and BCR signalling pathways seen in ABC DLBCL, 
agents targeting these pathways are under evaluation in this subtype. For example, 
bortezomib, which prevents the degradation of IκB, has shown benefit when combined with 
chemotherapy in relapsed patients with ABC subtype (Dunleavy et al., 2009). An ongoing 
clinical trial, REMoDL-B, is evaluating the addition of bortezomib to R-CHOP as front line 
therapy in patients with ABC DLBCL. In a phase 1/2 clinical trial ibrutinib, an inhibitor of BTK, 
induced complete or partial responses in 37% of ABC DLBCL cases versus 5% of those with GCB 
DLBCL (Wilson et al., 2015). A phase 3 clinical trial, PHOENIX, is currently evaluating the 
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addition of ibrutinib to R-CHOP in non-GCB DLBCL. Additionally, idelalisib a selective inhibitor 
of PI3K, has indicated potential in chronic lymphocytic leukaemia (CLL) and indolent NHL, but 
has not been assessed in DLBCL (Gopal  et al., 2014) (Furman  et al., 2014). Although PI3K is 
an important component of the BCR pathway, due to the frequent activation of the PI3K 
pathway observed in GCB DLBCL, this drug may be of potential therapeutic benefit in this 
subtype as well as in ABC DLBCL (Pfeifer et al., 2013). 
BCL2 targeting therapy 
BCL2 is frequently overexpressed in both GCB and ABC DLBCL. This over expression has been 
shown to have a negative impact on the outcome for patients with GCB DLBCL and “dual 
expresser” lymphomas (Johnson et al., 2012, Iqbal et al., 2011). A potent selective inhibitor, 
known as ABT-199, showed responses in 38% of relapsed DLBCL patients in a phase I clinical 
study which has led to combination trials being investigated (Souers et al., 2013, Seymour et 
al., 2013).  
Therapies targeting angiogenesis and the microenvironment 
Due to the importance of the microenvironment in the pathogenesis of DLBCL, therapies that 
target this component are of great interest. One such agent, lenalidomide, has been shown to 
have pleiotropic activities including immunomodulatory, anti-angiogenic as well as direct 
tumour cell effects (reviewed in Kritharis et al., 2015). Lenalidomide treatment was well 
tolerated and demonstrated an overall response rate of 35% in a phase II clinical trial of 
relapsed/refractory aggressive B-cell NHLs (Witzig et al., 2011). It has been shown to be safely 
combined with R-CHOP in many studies and appears to overcome the negative prognostic 
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impact of ABC DLBCL versus GCB DLBCL (in patients treated with R-CHOP, progression free 
survival was 28% versus 64%; p< .001, in non-GCB DLBCL versus GCB DLBCL, respectively. In 
patients treated with R-CHOP plus lenalidomide there was no difference in progression free 
survival in GCB DLBCL versus ABC DLBCL, 60% versus 59%; p=.83) (Nowakowski et al., 2011, 
Vitolo et al., 2014, Nowakowski et al., 2015). As a result, a phase III clinical trial (ROBUST) is 
investigating the effects of lenalidomide plus R-CHOP in untreated patients with ABC DLBCL.  
The results of clinical trials of anti-angiogenic therapies targeting the vascular endothelial 
growth factor (VEGF) signalling pathway have shown limited potential. The VEGF inhibitor, 
bevacizumab, showed only modest clinical activity in patients with relapsed NHL when 
delivered as a single agent or in combination with R-CHOP as first line treatment (Stopeck et 
al., 2009, Ganjoo et al., 2006). A phase III study of bevacizumab combined with R-CHOP in 
DLBCL patients (MAIN trial) was stopped early following a safety and efficacy analysis due to 
increased cardiotoxicity and without prolonging progression free survival (Seymour et al., 
2014). Therefore, agents targeting alternative pathways are required to target angiogenesis 
in lymphoma patients. Alternatively, patients need to be selected for these therapies at 
diagnosis on the basis of an angiogenic phenotype.
|25 
 
1.2. SPHK1-S1P signalling 
1.2.1 Introduction 
Sphingolipids are one of the basic components of the biological membrane present in all 
eukaryotic cells. Sphingolipid metabolism leads to the formation of polar lipid mediators such 
as sphingosine 1-phosphate (S1P). Originally, S1P was believed to be an intermediate in the 
detoxification of sphingosine following its phosphorylation and degradation. However, S1P 
was later shown to regulate cell growth and suppress programmed cell death (Zhang et al., 
1991, Cuvillier et al., 1996). S1P is now recognised as a potent, bioactive lipid mediator that 
regulates many cellular processes such as cell migration, proliferation and survival in both 
pathological and physiological settings. 
1.2.2 S1P synthesis and release  
S1P levels in cells are controlled by the balance between its formation and degradation. De 
novo synthesis of S1P occurs at the endoplasmic reticulum by condensation of serine and 
palmitate by serine palmitoyltransferase. S1P is also generated via sphingolipid turnover of 
the plasma membrane via the action of  sphingomyelinase which generates the intermediate  
ceramide (Hannun and Obeid, 2008). Ceramide is further metabolised by ceramidase, which 
yields sphingosine. Subsequent production of S1P is via the phosphorylation of sphingosine by 
sphingosine kinases (SPHK1 and SPHK2). S1P is degraded via two separate pathways; it can 
either be dephosphorylated to sphingosine mediated by specific S1P phosphatases (SGPP1 
and SGPP2) or irreversibly degraded to hexadecenal and phosphoethanolamine by S1P lyase 
(SGPL1) (Figure 1.7A).
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Figure 1.7: Sphingolipid metabolism. (A) The pathway of sphingolipid metabolism is shown. (B) S1P 
and ceramide have opposing functions, which makes their balance determine cell fate. This is 
referred to as the ‘sphingolipid rheostat’. 
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Following its production, S1P can be exported out of the cell by adenosine triphosphate (ATP)-
binding cassette multi-drug resistant transporters proteins such as ABCC1 and ABCA1 and the 
more recently identified transporter like protein SPNS2 (Mitra et al., 2006, Sato et al., 2007, 
Hisano et al., 2011). S1P is present in high concentrations in the circulation (between 0.1 – 4 
µM) (Hanel et al., 2007). This S1P originates from different sources, with erythrocytes being 
the main blood cell store of S1P. S1P is also released from activated platelets and the vascular 
endothelium (Pappu et al., 2007, Venkataraman et al., 2008, Yatomi et al., 2001). Although 
S1P concentrations are high in blood and lymph, the concentrations are low in tissue 
interstitial fluids, this gives rise to an S1P gradient. This S1P gradient is essential for 
lymphocyte egress (discussed below; Section 1.2.9.4) (Cyster and Schwab, 2012, Schwab et 
al., 2005). Circulating S1P is bound to chaperone proteins including high density lipoprotein 
and albumin (Murata et al., 2000). 
Extracellular S1P, produced by SPHK1, activates a family of G-protein-coupled receptors 
(GPCRs), a process known as “inside-out” signalling, whereas intracellular S1P, produced by 
SPHK2, acts as a second messenger by directly binding to intracellular protein targets (Spiegel, 
1999, Takabe et al., 2008) (Figure 1.8).  
1.2.3 Sphingolipid rheostat 
S1P enhances growth and survival in diverse cell types (Spiegel and Milstien, 2003). By 
contrast, ceramide and sphingosine are important mediators of stress responses and induce 
apoptosis and cell cycle arrest (Cuvillier et al., 1996, Obeid et al., 1993). Death inducers such 
as tumour-necrosis factor α (TNFα), FAS/FAS ligand, growth factor withdrawal and increased 
levels of DNA damage all increase ceramide production (Ogretmen and Hannun, 2001). 
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Figure 1.8: SPHKs localisation, S1P synthesis and signalling. SPHK1 is located in the cytoplasm and 
forms S1P from sphingosine at the plasma membrane, which can be exported out of the cell by 
specific transporters. Binding to S1P receptors (S1PR 1-5), extracellular S1P can initiate downstream 
signalling pathways in an autocrine or paracrine manner. SPHK2 is localised to the endoplasmic 
reticulum (ER), the mitochondrion and the nucleus. S1P produced in the nucleus and the 
mitochondria have direct intracellular targets which include histone deacetylases (HDACs) in the 
nucleus and prohibitin 2 (PHB2) in the mitochondria.  
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It is well established that ceramide has several targets which mediate its apoptotic function 
such as protein phosphatases 1, 2 (PP1 and PP2), cathepsin D and PKC (Heinrich et al., 2000, 
Wang et al., 2005). 
These opposing roles between ceramide/sphingosine and S1P led to the concept of the 
“sphingolipid rheostat” whereby the dynamic balances between these metabolites can 
determine cell fate (Cuvillier et al., 1996) (Figure 1.7B).  
1.2.4 Sphingosine kinase isoforms 
SPHKs are evolutionary well conserved lipid kinases expressed in humans, mice, yeast and 
plants with homologues in worms and flies. Two mammalian SPHKs have been characterised, 
these are known as SPHK1 (43kDa) and SPHK2 (65kDa). The genes for SPHK1 and SPHK2 are 
located on different chromosomes, SPHK1 is present at 17q25.2 whereas SPHK1 is located at 
19q13.2 (Kohama et al., 1998, Liu et al., 2000a). There are five highly conserved domains 
within SPHKs (C1-C5) with the catalytic domain located within C1-C3 and the ATP-binding site 
for S1P production is situated within the C2 domain (Takabe et al., 2008).  
1.2.5 Localisation and activation of sphingosine kinases 
 SPHK1 and SPHK2 differ in their subcellular localisation, with SPHK1 being mainly cytosolic 
and SPHK2 mainly nuclear thereby creating distinct pools of S1P (Figure 1.8).  
SPHK1 can be activated by multiple signals including GPCRs and tyrosine kinase agonists, 
proinflammatory cytokines, calcium and protein kinase activators, Ig receptors and small 
GTPases (Taha et al., 2006a, Maceyka et al., 2002). Following its activation, SPHK1 translocates 
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to the plasma membrane where it produces S1P from its substrate sphingosine. Additionally, 
this translocation results in localised production of S1P in the vicinity of membrane transport 
proteins and cell surface S1P receptors. SPHK1 translocation to the plasma membrane is 
dependent upon its phosphorylation on Ser225 by ERK1 and ERK2 (Pitson et al., 2003a). This 
dependency was highlighted by the inability of a phosphorylation deficient SPHK1 mutant to 
translocate to the plasma membrane and to increase proliferation and survival when over-
expressed (Pitson et al., 2005). Recent studies have identified a critical role for the calcium-
myristoyl switch protein, calcium and integrin binding protein 1 (CIB1), in the mechanism of 
SPHK1 translocation to the plasma membrane (Jarman et al., 2010). CIB1 interacts with SPHK1 
in a calcium dependent manner at a calmodulin binding site of SPHK1. Following calcium 
binding, CIB1 translocates to the plasma membrane which provides a mechanism for active 
translocation of SPHK1 to this location (Jarman et al., 2010). 
The regulation of SPHK2 is less well defined. SPHK2 is activated by a number of agonists 
including TNFα, interleukin 1β (IL1β) and epidermal growth factor (EGF) (Chun, 2013). 
Although the activating phosphorylation site of SPHK1 is not conserved in SPHK2, studies have 
also suggested that SPHK2 can be activated via its phosphorylation by ERK1 and ERK2, 
although the exact site(s) of phosphorylation are yet to be elucidated (Hait et al., 2007).  
Phosphorylation of SPHK2 also appears to play a role in its subcellular localisation. SPHK2 is 
located mainly in the nucleus or at the endoplasmic reticulum, however upon phosphorylation 
by PKD, SPHK2 is exported from the nucleus to the cytoplasm (Maceyka et al., 2005, Igarashi 
et al., 2003, Ding et al., 2007). 
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Although SPHK1 and SPHK2 produce distinct pools of S1P, SPHK1 and SPHK2 single knockout 
mice develop and reproduce normally. However, the double knockout is embryonically lethal 
due to severely disturbed neurogenesis and angiogenesis (Mizugishi et al., 2005).  
1.2.6 Role of intracellular S1P 
Although there is an abundance of evidence that “inside out” SPHK1 derived S1P signalling 
regulates many cellular processes, much less is known about the functions of intracellular S1P 
produced by SPHK2. Recent reports have demonstrated that intracellular S1P binds to and 
inhibits histone deacetylases (HDAC1 and HDAC2) (Figure 1.8). SPHK2 was also detected at the 
promotors of the transcriptional regulator c-fos and the cyclin dependent kinase inhibitor p21, 
leading to the S1P-mediated regulation of histone acetylation resulting in their enhanced 
transcription (Hait et al., 2009). 
Intracellular S1P also plays a role in TNFα induced activation of NF-κB signalling and is a co-
factor required for the ligase activity of TNF receptor-associated factor 2 (TRAF2) (Alvarez et 
al., 2010). TRAF2 is an adaptor protein that is involved in the ubiquitination of RIP1, a critical 
event in the activation of NF-κB in response to TNFα.  
Intracellular S1P has suggested roles in mitochondrial respiration via binding to prohibitin 2 
(PHB2), a protein which regulates mitochondrial assembly and function. SPHK2 knockout mice 
have reduced mitochondrial respiration due to defective assembly and activity of cytochrome 
oxidase, suggesting that the interaction of S1P with PHB2 is important for these processes 
(Strub et al., 2011).  
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1.2.7 Effects of SPHK2 expression 
There are conflicting reports of SPHK2 functions. Early reports indicated that overexpression 
of SPHK2 causes the suppression of cell growth and cell cycle arrest via inhibition of DNA 
synthesis (Igarashi et al., 2003). Apoptosis following mitochondrial release of cytochrome c 
and activation of caspase 3 has also been shown to follow SPHK2 overexpression (Liu et al., 
2003). These effects were shown to be the result of the SPHK2 Bcl-2 homology 3 (BH3) binding 
domain which sequesters the anti-apoptotic protein BCL2L1 inhibiting its function (Liu et al., 
2003).  
However, other studies suggest pro-survival functions for SPHK2. For example, SPHK2 
knockdown increases the sensitivity of breast and colon cancer cells to doxorubicin- induced 
apoptosis (Sankala et al., 2007). Furthermore, knockdown of SPHK2 in glioblastoma cells 
inhibits their proliferation (Van Brocklyn et al., 2005).  
1.2.8 S1P receptor signalling 
Five high-affinity S1P GPCRs have been described: S1PR1 (EDG1), S1PR2 (EDG5), S1PR3 
(EDG3), S1PR4 (EDG6) and S1PR5 (EDG), encoded by endothelial differentiation genes (EDG). 
Signalling through these receptors, S1P can mediate both paracrine and autocrine signalling 
(Alvarez et al., 2007) (Figure 1.8). S1P receptors are 7 transmembrane proteins that couple to 
a variety of heterotrimeric G proteins. A schematic representation of the binding specificities 
can be seen in (Figure 1.9). 
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Figure 1.9: Downstream signalling pathways of S1P receptors. S1P is a ligand for five receptors 
S1PR1-5. Each S1P receptor is coupled to different G proteins which activate different signalling 
pathways.   
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S1PR1, S1PR2 and S1PR3 are widely expressed in most mammalian tissues, whereas S1PR4 
and S1PR5 are mainly expressed in lymphoid cells and brain, respectively (Brinkmann, 2007, 
Chun et al., 2010).  The response to S1P is governed by the mix of these different receptors on 
the cell surface. 
S1PR1 
S1PR1 was cloned in 1990 when it was discovered that one of the immediate early response 
genes induced during angiogenesis in human umbilical vein endothelial cells (HUVEC)  
encoded a GPCR, and it was named endothelial differentiation gene-1 (EDG1) (Hla and Maciag, 
1990). The ubiquitous expression of S1PR1 is observed in many tissues and cell types (Chun, 
2013). S1PR1 is abundant in endothelial cells but has also been shown to be expressed by 
many other cells including vascular smooth muscle cells, fibroblasts and epithelial cells as well 
as cells of the immune system such as T and B cells, macrophages, dendritic cells and natural 
killer cells (Goetzl et al., 2004, Chun, 2013). Following S1P binding, S1PR1 exclusively couples 
to Gi protein which leads to ERK and PI3K/AKT pathway activation, resulting in prosurvival and 
mitogenic signalling (Figure 1.10). Additionally, S1PR1 signalling leads to the activation of the 
Rho family small GTPase Rac, which is essential for cell migration and lamellipodia formation. 
This results in S1PR1 directed cell migration towards S1P. Moreover, S1PR1 activates 
phospholipase C (PLC) and Ca2+ mobilisation via Gi (Okamoto et al., 1998, Rivera and Chun, 
2008).  
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S1PR2 
S1PR2 was first cloned as a putative GPCR from a rat aortic cDNA library in an attempt to 
explore a novel signalling system in the vasculature (Okazaki et al., 1993). It was later 
identified by many groups as a high affinity S1P receptor (Gonda et al., 1999, Takuwa et al., 
2011). Like S1PR1, S1PR2 is widely expressed. However, unlike S1PR1, S1PR2 couples to 
multiple heterotrimeric G proteins including Gi, Gq and G12/13. Of these, G12/13 coupling to Rho 
activation is the most prominent (Windh et al., 1999, Okamoto et al., 2000, Takuwa, 2002). 
Contrary to the action of S1PR1, S1PR2 exerts an inhibitory effect on Rac, via downstream 
activation of Rho, which results in inhibition of cell migration (Estrada et al., 2008, Takuwa, 
2002) (Figure 1.10). Additionally, S1PR2 mediated Rho activation results in inhibition of AKT 
therefore inhibiting rather than promoting cell proliferation (Sanchez et al., 2005, Schuppel et 
al., 2008) (Figure 1.10). S1PR2 signalling also stimulates PLC and Ca2+ mobilisation through Gq, 
and ERK and PI3K activation via Gi (Takuwa et al., 2001, Takuwa et al., 2002).    
S1PR3 
S1PR3 was isolated as an orphan GPCR gene with a high affinity to S1P. Like S1PR2, S1PR3 
couples to multiple G proteins,  activating PLC and Ca2+ via Gq and ERK, PI3K and Rac via Gi, 
predominantly inducing cell survival, proliferation and migration to S1P (Windh et al., 1999, 
Okamoto et al., 1999) (Figure 1.10). S1PR3 also couples to G12/13 activating Rho, although this 
is to a much lower extent than S1PR2 (Okamoto et al., 2000).  
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S1PR4 
S1PR4 was identified from murine and human dendritic cells as an orphan GPCR and later 
found to a high affinity receptor for S1P (Ishii et al., 2004). S1PR4 couples with Gi and G12/13 
mediating S1P-induced ERK, PLC and Rho activation as well as Ca2+ mobilisation, cytoskeleton 
rearrangement and cell migration (Ishii et al., 2004). In contrast to S1PR1-3, S1PR4 expression 
is restricted to lymphoid tissues indicating a role in regulation of the immune system 
S1PR5 
S1PR5 was isolated as an orphan GPCR from rat pheochromocytoma (PC12) cells and later 
found to be a high affinity S1P receptor (Malek et al., 2001, Glickman et al., 1999). S1PR5 can 
couple with Gi and G12/13 and is highly expressed in white matter and cells of the  
oligodendrocyte lineage in the rat brain, suggesting a potential role in the maturation of 
oligodendrocytes (Terai et al., 2003).     
.
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Figure 1.10: The differential effects of S1P receptor signalling: S1PR1 couples exclusively to Gi to 
activate ERK (MAPK) and PI3K/AKT/Rac pathways resulting in the stimulation of cell proliferation 
and migration. S1PR2 couples to multiple G proteins, especially to G12/13 resulting in Rho 
activation, leading to the inhibition of Rac and cell migration as well as inhibition of cell 
proliferation due to the inhibition of AKT. S1PR3 activates the PLC- Ca
2+ 
pathway via Gq and the 
ERK and PI3K pathways via Gi.  (Reproduced from: Takuwa et al. 2001) 
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1.2.9 Effects of SPHK1 expression 
SPHK1 has been shown to increase cell survival, proliferation and migration. It also promotes 
angiogenesis and lymphocyte migration leading many to define SPHK1 as an oncogene (Pyne 
et al., 2012, Maceyka et al., 2002, Maceyka et al., 2012). Main findings are discussed below. 
1.2.9.1 Expression of SPHK1 in cancer 
In early studies, the overexpression of SPHK1 in NIH3T3 fibroblasts was shown to result in 
neoplastic transformation and the ability to form tumours when allografted into mice (Xia et 
al., 2000). This effect was not observed in NIH3T3 fibroblasts expressing a dominant negative 
kinase dead SPHK1 mutant or in the presence of an SPHK1 inhibitor (Xia et al., 2000). 
Subsequently, numerous studies showed SPHK1 expression is increased in many cancer types; 
in many cases correlating with increased tumour grade and reduced patient survival 
(summarised in Table 1.2). 
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Table 1.2: Increased SPHK1 expression in human tumours and clinical correlation 
Tumour 
Location 
mRNA or 
Protein 
Number of 
Tumour Samples 
Clinical correlation References 
Gastric 
mRNA 
27  undetermined 
(French et al., 
2003) 
4  undetermined 
(Li et al., 2009) 
Protein 175  
Increased expression of SPHK1 
correlates with reduced patient 
survival 
Glioblastoma mRNA 48  
Increased expression of SPHK1 
correlates with reduced patient 
survival 
(Van Brocklyn et 
al., 2005) 
Astrocytoma Protein 243  
Increased expression of SPHK1 
correlates with reduced patient 
survival; expression increases 
with clinical grade 
(Li et al., 2008a) 
Breast mRNA 1269 
Increased expression of SPHK1 
correlated with poor prognosis; 
higher expression in ER negative 
tumours 
(Ruckhaberle et 
al., 2008) 
Colon 
mRNA 35 Undetermined 
(French et al., 
2003) 
Protein 47  
Higher expression of SPHK1 in 
primary cancer with metastases 
than in those without 
metastases 
(Kawamori et al., 
2009) 
Kidney mRNA 20 undetermined 
(French et al., 
2003) 
Lung 
mRNA 21 undetermined 
(French et al., 
2003) 
Protein 25 undetermined 
(Johnson et al., 
2005) 
Non-Hodgkin 
Lymphoma 
mRNA 
44 
Increased expression of SPHK1 
correlates with increased clinical 
grade 
(Bayerl et al., 
2008) Protein 
Ovary mRNA 14 undetermined 
(French et al., 
2003) 
Rectum mRNA 18 undetermined 
(French et al., 
2003) 
Uterus mRNA 42 undetermined 
(French et al., 
2003) 
Pancreas Protein 60 undetermined 
(Guillermet-
Guibert et al., 
2009) 
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Constitutively active mutant Ras has been shown to induce the transcriptional upregulation 
of SPHK1 (Xia et al., 2000). Similarly, v-Src expression has been shown to stabilise SPHK1 mRNA 
leading to increased SPHK1 mRNA levels and protein over expression (Sobue et al., 2008a). 
The degradation of SPHK1 is dependent upon p53, and loss of p53, which is frequently 
observed in human cancers, results in reduced SPHK1 degradation. SPHK1 is also proteolysed 
following genotoxic stress in a p53-dependent manner (Heffernan-Stroud et al., 2012).  
Mice lacking both p53 alleles develop thymic lymphoma and were shown to display elevated 
levels of SPHK1/S1P and decreased levels of ceramide in the thymi. Notably, deletion of SPHK1 
in p53 deficient mice completely abrogated thymic lymphomas and prolonged survival by 30% 
(Heffernan-Stroud et al., 2012). The SPHK1 gene has two hypoxia-inducible factor (HIF) 
responsive elements in its promotor region, through which HIF1α and HIF2α contribute to 
upregulate SPHK1 expression (Anelli et al., 2008, Schwalm et al., 2008).  
1.2.9.2 Contribution of SPHK1-S1P signalling to cancer cell survival and treatment resistance 
SPHK1 overexpression is protective against a diverse range of pro-apoptotic stimuli including 
TNFα, hydrogen peroxide, serum withdrawal, androgen depletion and amyloid β peptide in 
many biological settings (Cuvillier et al., 2010). Knockdown of SPHK1 has been shown to inhibit 
cell proliferation and/or trigger apoptosis in prostate, pancreatic, leukaemic, glioma and 
breast cancer cells (Akao et al., 2006, Pchejetski et al., 2005, Guillermet-Guibert et al., 2009, 
Baran et al., 2007, Kapitonov et al., 2009, Taha et al., 2006b). The mechanism for this function 
is likely to be as a result of enhanced SPHK1 activity reducing the levels of ceramide by driving 
ceramide metabolism towards the synthesis of growth promoting S1P. S1P has also been 
shown to inhibit caspase-dependent apoptosis by blocking cytochrome c release (Cuvillier and 
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Levade, 2001). S1P also increases the expression of the anti-apoptotic proteins BCL2 and 
induced myeloid leukaemia cell differentiation protein (MCL1), while downregulating the pro-
apoptotic proteins, BCL2, associated agonist of cell death (BAD) and BCL2 associated X protein 
(BAX) (Sauer et al., 2005, Li et al., 2008c, Avery et al., 2008).  
Due to these anti-apoptotic effects of S1P signalling, there are many reports that suggest that 
SPHK1 expression contributes to treatment resistance (Pchejetski et al., 2005, Baran et al., 
2007, Sobue et al., 2008b). Many therapies against cancer utilise the apoptotic machinery of 
cells and the generation of ceramide. For example, taxol treatment of prostate cancer cells 
induces ceramide production whereas the inability to produce ceramide is linked to therapy 
resistance (Ogretmen and Hannun, 2001). Increased ceramide production following treatment 
may not be sufficient to push the cells towards apoptosis without also inhibiting S1P 
production as a result of SPHK1 expression. This was shown by the correlation observed 
between SPHK1 expression and resistance to irradiation in prostate cancer cells. In radiation 
resistant cells, SPHK1 activity was not altered following ionising radiation, whereas SPHK1 
activity was greatly reduced in radiosensitive cells (Nava et al., 2000). The relationship 
between SPHK1 expression and resistance to chemotherapy has also been showed in prostate 
cancer cells; using an orthotopic model for prostate cancer, Pchejetski and colleagues (2005) 
demonstrated that animals injected with PC-3 cells overexpressing SPHK1 developed larger 
tumours which were resistant to docetaxel treatment. The increase in ceramide normally 
detected following docetaxel treatment was reduced in those animals implanted with PC-3 
cells overexpressing SPHK1 compared to controls.  
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1.2.9.3 S1P signalling pathways in cancer 
S1P signalling has also been identified as a crucial element involved in the persistent activation 
of STAT3 in tumour cells and the tumour microenvironment (Lee et al., 2010).  Aberrant STAT3 
activation in cancer cells has emerged as a major mechanism for cancer initiation and 
progression. It was shown that S1PR1 was elevated in STAT3 positive tumours and that STAT3 
is a transcriptional regulator of S1PR1 expression.  The enhanced S1PR1 expression activates 
STAT3 and upregulates interleukin-6 (IL6) production, a pro-inflammatory cytokine crucial for 
STAT3 activation. It was shown that silencing S1PR1 in tumour cells or immune cells inhibited 
tumour STAT3 activity, reducing tumour growth and metastasis (Lee et al., 2010). Therefore 
this feed-forward mechanism results in persistent STAT3 activation and is important in 
malignant progression (Lee et al., 2010). In ABC DLBCL, high levels of expression and activation 
of STAT3 have been reported (Ding et al., 2008). Consistent with these findings, it was shown 
that persistent activated STAT3 colocalises with high S1PR1 expression in ABC DLBCL. 
Inhibition of S1PR1 affected the downstream signalling of STAT3 involved in cell survival, 
proliferation and invasion (Liu et al., 2012).  
1.2.9.4 Contribution of SPHK1-S1P signalling to cancer cell invasion and metastasis 
S1P can also regulate cell migration, either negatively or positively, governed by the 
expression of different S1P receptors on the cell surface (Figure 1.10). This phenomenon is 
best demonstrated by the physiological role of S1P in the GC reaction and lymphocyte egress. 
The anti-migratory receptor S1PR2 is highly expressed by GC B cells. S1PR2 expression has 
been shown to be vital for GC B cell positioning and confinement to the GC; best demonstrated 
by S1PR2-deficient mice which display large GC outgrowths which lead to an expansion of the 
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lymph node and a loss of lymphoid architecture (Cattoretti et al., 2009, Green and Cyster, 
2012). 
Lymphocytes exit lymphoid structures into lymphatic vessels, a process known as lymphocyte 
egress. It has been demonstrated that lymphocyte egress is dependent upon the cellular 
expression of the pro-migratory receptor S1PR1 and increased concentrations of S1P in the 
blood and lymph compared to tissue (Cyster, 2005). The immunosuppressive S1P receptor 
agonist, FTY720, leads to lymphopenia in several animal models and in humans (discussed 
below; Section 1.2.10.2) (Chiba et al., 1998, Yagi et al., 2000, Mandala et al., 2002).  
Through these activities, S1P signalling can stimulate the motility of cancer cells via S1PR1 or 
S1PR3; in contrast S1P inhibits cancer cell motility through S1PR2. This is illustrated by the 
S1P-induced migration of gastric tumour cells which exclusively express S1PR3 and the S1P-
induced inhibition of migration of gastric tumour cells which predominantly express S1PR2 
(Yamashita et al., 2006). Additionally S1P signalling can induce migration in many other cancer 
cell types (Pyne and Pyne, 2010, Park et al., 2007).  
There are reports of the altered expression and or/ mutation of the S1P receptors in cancer. 
By two years of age, roughly half of S1PR2-deficient mice develop tumours that may be 
classified as DLBCL (Cattoretti et al., 2009). Furthermore, S1PR2 has been shown to be 
mutated in ~25% of patients with DLBCL (Cattoretti et al., 2009).  
1.2.9.5 Contribution of SPHK1-S1P signalling to tumour angiogenesis 
S1P has been shown to play a major role in vascular functions. In 1999, two papers were 
published which revealed that S1P played a potential role in angiogenesis (English et al., 1999, 
|44 
 
Lee et al., 1999). It was shown that S1P stimulated DNA synthesis and the chemotactic motility 
of HUVEC in a dose dependent manner. The authors reported the S1P-induced tube formation 
of HUVEC in Matrigel. This observation was confirmed in vivo by a study which showed that 
S1P promotes angiogenesis in a Matrigel plug assay (Lee et al., 1999). S1P has also been shown 
to prevent apoptosis of endothelial cells induced by serum starvation and TNFα (Xia et al., 
1999). The essential role of S1P signalling in vascular development is well demonstrated in 
S1PR1 knockout mice, which display impaired vascular maturation leading to embryonic 
haemorrhage and intrauterine death (Liu et al., 2000b). Additionally, as mentioned earlier, 
mice deficient for SPHK1 and SPHK2 show severe loss of vessel stability also leading to 
embryonic lethality (Mizugishi et al., 2005).  
Tumour angiogenesis is essential for the survival and development of a tumour greater than 
2 mm3 in size (Folkman, 1971). Tumour blood vessels are a key part of the tumour 
microenvironment required for the delivery of nutrients and oxygen and essential for tumour 
growth and metastasis (Folkman, 1971). Tumour angiogenesis is a complex multistep process 
driven by cellular transformation and tumour-associated hypoxia (Tonini et al., 2003). Tumour 
cells secrete a number of pro-angiogenic growth factors including platelet derived growth 
factor (PDGF), VEGF and basic fibroblast growth factor (bFGF), which recruit endothelial cells 
and promote their proliferation and the formation of vessels (Carmeliet and Jain, 2000, Tonini 
et al., 2003). Furthermore, infiltrating stromal cells can also be stimulated to produce growth 
factors that support the angiogenic process (Murdoch et al., 2008). 
As well as developmental angiogenesis, S1P signalling has been shown to play a role in tumour 
angiogenesis. Anelli et al. (2010) showed that S1P secreted from HEK cells and tumour cells 
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overexpressing SPHK1 induced endothelial cell migration and tube formation in a co-culture 
system. S1PR1 expression in vessels has been shown to be upregulated at the sites of tumour 
implantation in a Lewis lung carcinoma xenograft mouse model (Chae et al., 2004). Silencing 
of S1PR1 by repeated local injections of S1PR1 siRNA into established tumours suppressed 
tumour angiogenesis and vascular stabilisation with inhibition of tumour growth (Chae et al., 
2004). Furthermore, it has been shown that targeting the S1P signalling pathway inhibits 
angiogenesis and tumour cell proliferation in vivo, to a greater extent than those observed 
with anti-VEGF antibodies; it has been shown that anti-S1P antibody suppresses VEGF and FGF 
induced angiogenesis in Matrigel plugs in mice, which suggests S1P plays a role in VEGF and 
FGF mediated angiogenesis (Visentin et al., 2006, LaMontagne et al., 2006, Azuma et al., 
2002). These observations indicate that S1PR1 expressed in tumour-associated endothelium 
is crucial for tumour angiogenesis. 
1.2.10 Targeting S1P signalling in cancer 
Due to the aforementioned role of SPHK1-S1P signalling in cancer, much emphasis is now 
placed on the development of compounds that target this signalling pathway for treatment. 
Strategies which have been used to limit the effects of S1P signalling in cancer include 
sequestering released S1P, inhibition of SPHK1 and/or inhibition of specific S1P receptors. 
1.2.10.1 S1P antibodies 
Anti-S1P monoclonal antibody (Sphingomab) sequesters S1P preventing it from binding to its 
receptors. Sphingomab has been shown to have high specificity for S1P and does not cross 
react with other structurally related lipids such as lysophosphatidic acid (LPA) (O'Brien et al., 
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2009). Sphingomab reduced tumour progression in murine xenograft models through 
inhibition of tumour angiogenesis, as shown by reduced microvessel density, and inhibition of 
S1P stimulated release of pro-angiogenic cytokines VEGF, IL6 and interleukin-8 (IL8) (Visentin 
et al., 2006). Sonepcizumab (humanised form of Sphingomab) has completed a Phase I clinical 
trial in cancer patients (ClinicalTrials.gov Identifier: NCT00661414). Sonepcizumab was 
administered as a single agent weekly to patients with refractory advanced solid tumours at 
doses between 1 and 24 mg/kg with the objectives to characterise the safety, tolerability and 
dose-limiting toxicities of the drug. Sonepcizumab was well tolerated across the range of doses 
tested and there were no dose-limiting toxicities observed. Of the 21 patients, 11 had stable 
disease for 2 months or longer, including one patient with an aggressive metastatic melanoma 
showing stable disease for 8 months, one patient with an adenoid cystic tumour treated for 
over 12 months without disease progression and another patient with a carcinoid tumour who 
was still being treated at the date of a report 26 months later (Sabbadini, 2011). 
1.2.10.2 S1P receptor agonists 
Several S1P receptor antagonists are available, in particular against S1PR1 and S1PR3. One 
such compound is the immunosuppressant FTY720 (fingolimod). FTY720 is an analogue of 
sphingosine, which is taken up by cells and phosphorylated by SPHK2 to yield biologically 
active FTY720-phosphate (FTY720-P) (Sanchez et al., 2003). FTY720-P binds to S1P receptors 
S1PR1, 3, 4 and 5. FTY720-P is an S1PR1 receptor agonist and FTY720-P binding induces S1PR1 
internalisation and degradation resulting in prolonged receptor downregulation (Matloubian 
et al., 2004). In this way, lymphocytes are deprived of the signal necessary for their egress 
from secondary lymphoid organs resulting in lymphopenia following FTY720 treatment (Graler 
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and Goetzl, 2004, Matloubian et al., 2004, Cyster, 2005). These effects are advantageous for 
the treatment of autoimmune diseases and FTY720 has been approved by the Food and Drug 
Administration for the treatment of relapsing remitting multiple sclerosis. There have been 
many examples of the use effectiveness of FTY720 in vivo showing inhibition of tumour growth 
and angiogenesis in various mouse tumour models including renal, bladder, prostate, breast, 
hepatocellular carcinoma and melanoma (Ubai et al., 2007, Azuma et al., 2003, Chua et al., 
2005, Azuma et al., 2002, Ho et al., 2005, LaMontagne et al., 2006).  However, FTY720 has not 
been tested in a clinical trial of cancer patients. 
1.2.10.3 Sphingosine kinase inhibitors 
SPHK1 inhibitors might exert their effects not only by the reduction in S1P production but also 
by increasing the levels of pro-apoptotic ceramide and sphingosine. One of the first 
compounds identified as an inhibitor of SPHK activity was DHS (Saphingol). Later it was 
discovered that DMS, a methylated metabolite of sphingosine, was more potent that DHS. As 
a result DMS has been used most widely as a pharmacological inhibitor of sphingosine. 
However, neither DHS nor DMS are considered as specific kinase inhibitors as they inhibit both 
SPHK1 and SPHK2, ceramide kinase, PKC, protein dependent protein kinase, 3-
phosphoinositide-dependent kinase and casein kinase II (reviewed in: Takabe et al., 2008). 
DHS and DMS have both been evaluated in pre-clinical trials in animal models and DMS was 
shown to reduce gastric and lung tumour growth in vivo and decrease lung metastasis of 
melanoma cells (Endo et al., 1991, Okoshi et al., 1991). Although DHS and DMS have shown 
to inhibit tumour growth in vivo, they cause significant haemolysis and hepatotoxicity 
(Kedderis et al., 1995).  
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Non-lipid SPHK1 inhibitors (compounds SPHK1 I-V) have also been identified with nanomolar 
potencies, which are non-competitive inhibitors at the ATP binding site of SPHK1. SPHK1-II, 
known as SPHKi, which does not inhibit other kinases, inhibits the proliferation and induces 
apoptosis in various cancer cell lines. Additionally, SPHKi was shown to inhibit tumour growth 
in vivo (French et al., 2003). However, SPHKi has not been tested in clinical trials of patients.  
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1.3 Study aims 
SPHK1 has recently emerged as an important regulator of tumour cell growth, survival, 
metastasis and angiogenesis. These activities of SPHK1 are mainly a consequence of its ability 
to catalyse production of the bioactive signalling lipid, S1P. Importantly, new therapies 
targeting SPHK1-S1P signalling are being developed. This thesis explores the contribution of 
SPHK1-S1P signalling to the pathogenesis of DLBCL, and its potential therapeutic reversal, with 
a focus on tumour angiogenesis. The specific aims are to: 
1. Investigate the expression of SPHK1 in primary DLBCL. Describe the association 
between SPHK1 expression and that of angiogenesis-associated genes in primary 
DLBCL.  
2. Validate an in vitro model which can be used to study the effects of S1P signalling on 
the endothelial cell transcriptome. Use this model to define an S1P-induced 
endothelial cell gene signature and measure the extent to which this signature is 
expressed in primary DLBCL. 
3. Explore the phenotypic effects of the S1P-induced endothelial cell gene signature. 
4. Investigate the potential in vitro inhibition of S1P-induced signalling and gene 
expression in endothelial cells using SPHK1-S1P targeting drugs. 
5. Establish an in vivo model of DLBCL which can be used to study the potential 
therapeutic efficacy of these SPHK1-S1P targeting drugs in vivo. 
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CHAPTER TWO 
MATERIALS AND METHODS
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2.1 HUVEC isolation  
Endothelial cells were isolated from umbilical cords which were obtained from the Human 
Biomaterials Resource Centre (HBRC; University of Birmingham) with patient consent and 
ethical approval (No. RG_HBRC_14-180). The HUVEC were isolated using collagenase 
treatment as previously described (Jaffe et al., 1973).  Briefly, the umbilical cords were sprayed 
with 70% ethanol and checked for needle holes. The vein of the umbilical cord was then 
cannulated at each end and phosphate-buffered saline (PBS) was flushed through to remove 
any residual blood. Collagenase (type 2; Sigma-Aldrich Ltd., Gillingham, UK) dissolved in PBS 
(1 mg/ml) was pushed through the vein until it became visible in both ends of the cannula. 
Both cannulae were then securely sealed and the cord was incubated at 37°C for 15 minutes. 
The collagenase solution containing the HUVEC was then removed and the cells were pelleted 
by centrifugation (Eppendorf Centrifuge 5810R) at 200 g for 10 minutes and resuspended in 
culture medium.  
2.2 Cell culture 
2.2.1 Maintenance of cell lines 
All cells were maintained in the growth media detailed in Table 2.1 and incubated at 37 °C in 
a humidified atmosphere containing 5% carbon dioxide (Galaxy R CO2 Incubator; RS Biotech). 
At between 70 and 80% confluency, as determined by visual inspection under a microscope, 
cells were passaged to prevent over growth. For adherent cells, media was aspirated using a 
VACUSAFE aspirator (INTEGRA Biosciences AG) and the cells were washed twice with PBS.
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Table 2.1: Summary of cell lines and the culture media 
Cell line 
name 
Culture 
characteristics 
Cell type Culture Media 
HUVEC Adherent Human 
endothelial 
cell  
M199 (Sigma-Aldrich Ltd., Gillingham, 
UK) supplemented with 5% v/v foetal 
bovine serum (FBS), 5% endothelial cell 
growth supplement (ECGS; Caltag 
Medsystems), 1% v/v glutamine (Gibco, 
Life Technologies Ltd) and 1% v/v 
penicillin/streptomycin (P/S, Gibco, Life 
Technologies Ltd). 
sEnd-1 Adherent Murine 
endothelioma 
DMEM (Gibco, Life Technologies Ltd) 
supplemented with 10% v/v FBS and 1% 
v/v P/S 
HEK293 Adherent Human 
embryonic 
kidney 
DMEM supplemented with 10% v/v FBS 
and 1% v/v P/S 
A20 Suspension Murine B cell 
lymphoma 
RPMI 1640 (Gibco, Life Technologies Ltd) 
supplemented with 10% v/v FBS and 
0.05 mM 2-mercaptoethanol 
L428 Suspension Hodgkin 
lymphoma 
(human) 
RPMI 1640, supplemented with 10% v/v 
FBS and 1% v/v P/S. 
HT Suspension DLBCL 
(human) 
RPMI 1640 supplemented with 10% v/v 
FBS and 1% v/v P/S. 
Karpas 
422 
Suspension DLBCL 
(human) 
RPMI 1640 supplemented with 10% v/v 
FBS and 1% v/v P/S. 
U2932 Suspension DLBCL 
(human) 
RPMI 1640 supplemented with 10% v/v 
FBS and 1% v/v P/S. 
OCILY1 Suspension DLBCL 
(human) 
IMDM (Gibco, Life Technologies Ltd), 
supplemented with 10% v/v FBS and 1% 
v/v P/S.  
OCILY3 Suspension DLBCL 
(human) 
IMDM supplemented with 10% v/v FBS 
and 1% v/v P/S. 
OCILY7 Suspension DLBCL 
(human) 
IMDM supplemented with 10% v/v FBS 
and 1% v/v P/S. 
SUDHL4 Suspension DLBCL 
(human) 
RPMI 1640 supplemented with 10% v/v 
FBS and 1% v/v P/S. 
SUDHL5 Suspension DLBCL 
(human) 
RPMI 1640 supplemented with 10% v/v 
FBS and 1% v/v P/S. 
FARAGE Suspension DLBCL 
(human) 
RPMI 1640 supplemented with 10% v/v 
FBS and 1% v/v P/S. 
THP-1 Suspension Acute 
monocytic 
leukemia  
(human) 
RPMI 1640 supplemented with 10% v/v 
FBS and 1% v/v P/S. 
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Trypsin solution (Gibco, Life Technologies Ltd) was added to the cells and incubated at 37°C 
for 3 minutes to allow the cells to detach from the culture flask. The trypsin was neutralised 
by addition of medium. Both adherent and suspensions cells were pelleted by centrifugation 
at 200 g for 10 minutes and resuspended in fresh culture media to obtain the desired 
concentration. 
2.2.2 Cryopreservation of cells 
Cells were pelleted by centrifugation at 200 g for 5 minutes and resuspended in chilled 
freezing solution (90% v/v FBS (PAA the cell culture company, Somerset, UK), 10% v/v dimethyl 
sulphoxide (DMSO; Sigma-Aldrich Ltd., Gillingham, UK)).  Cells were transferred to 
cryopreservation tubes (Nunc® Cryo Tubes; Sigma-Aldrich Ltd., Gillingham, UK) and cooled 
overnight to -80°C in a cryo container (Nalgene® Mr. Frosty; Sigma-Aldrich Ltd., Gillingham, 
UK). Cells were transferred to the vapour phase of a -180°C liquid nitrogen freezer for storage.  
2.3 Preparation of S1P 
S1P (Sigma-Aldrich Ltd., Gillingham, UK) was dissolved by addition of methanol:water 95:5 to 
a final concentration of 0.5 mg/ml. The mixture was heated in a water bath at 65C for 10 
minutes and then briefly placed in an ultrasonic water bath. A 125 µM working solution was 
made by transferring 50 µl dissolved S1P to a glass vessel (Supelco; Sigma-Aldrich Ltd., 
Gillingham, UK) and the methanol:water solution allowed to evaporate. Low retention pipette 
tips (Plastibrand; Sigma-Aldrich Ltd., Gillingham, UK) were used to pipette S1P. To dissolve the 
S1P, 520 µl of 4 mg/ml fatty acid free bovine serum albumin (BSA; Sigma-Aldrich Ltd., 
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Gillingham, UK) in water was added at 37C and incubated for 30 minutes on a roller. S1P-BSA 
aliquots were stored at -20C for a maximum of 3 months.  
2.4 HUVEC stimulations 
HUVEC were grown in normal growth conditions on 6 well dishes (Corning, Sigma-Aldrich Ltd., 
Gillingham, UK) until they reached confluence. Sixteen hours prior to S1P stimulation, HUVEC 
were washed twice with PBS and media changed to M199 supplemented with 5% v/v FBS and 
1% v/v P/S, to deplete the HUVEC of ECGS. S1P was heated to 37C and then pipetted directly 
into the HUVEC media of the 6 well dish.  
Sphingomab and isotype control antibody (both LPath Inc., CA, USA) treatments were used at 
a concentration of 150 µg/ml per µM of S1P  (O'Brien et al., 2009) unless otherwise stated, 
and were  added to the medium at the same time as S1P. 
For FTY720 treatment experiments, HUVEC were treated with FTY720 (Sigma-Aldrich Ltd., 
Gillingham, UK) for 1 hour prior to S1P treatments. 
2.5 Transfection of HEK293 cells 
HEK293 cells were grown on 9 mm multi-spot coated microscope slides (Hendley-Essex, Essex, 
UK) overnight to 70% confluency. The cells were then washed with Opti-MEM (Thermo Fisher 
Scientific Inc., Waltham, MA, USA) before 70 μl of Opti-MEM was pipetted onto each spot of 
cells. A transfection reaction mix was made up of: 100 μl Opti-MEM, 2 μl lipofectamine reagent 
(Thermo Fisher Scientific Inc, Waltham, MA, USA) and 1 μg plasmid DNA (pcDNA3.1, 
pcDNA3.1-S1PR1, pcDNA3.1-S1PR2 or pcDNA3.1-S1PR3) kindly provided by Dr Ian Paterson 
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(University of Malaya, Kuala Lumpur), and incubated for 15 minutes. Ten μl of transfection 
reaction mix was pipetted into the 70 μl of Opti-MEM on the HEK293 cells, incubated for 4 
hours and then replaced with normal culture media. Twenty four hours later, the HEK293 cells 
were washed and fixed by submerging the microscope slide in PBS for 2 minutes followed by 
10% formal-saline solution (Genta Medical, York, UK) for 10 minutes. The HEK293 cells were 
air-dried and the slides stored at -20˚C until required.  
2.6 RNA analysis 
2.6.1 RNA extraction 
Total RNA was isolated using the QIAGEN RNeasy kits (QIAGEN Ltd., Manchester, UK) 
according to the manufacturer’s protocol. Briefly, cells were lysed in RLT buffer and 
homogenized by vigorous vortexing. Samples were then mixed 1:1 v/v with 70% ethanol and 
loaded on RNeasy spin columns. The column was centrifuged at 8000 g and washed with kit 
buffers. The columns were incubated for 15 minutes with DNase solution (RNase-Free DNase 
Set; QIAGEN Ltd., Manchester, UK) at room temperature to degrade contaminating DNA in 
the samples. This was followed by several wash steps. Finally, the RNA was eluted by addition 
of nuclease-free water (Promega UK Ltd., Hampshire, UK) to the membrane. The RNA 
concentration of the samples was measured on a NanoDrop ND-1000 spectrophotometer 
(Thermo Fisher Scientific Inc, Waltham, MA, USA) and the RNA stored at -80°C.  
2.6.2 Preparation of cDNA 
Complementary DNA (cDNA) was synthesised from 500 ng of total RNA extracted from 
samples. Five hundred ng of RNA was added to 4 μl of qScript cDNA SuperMix (Quanta 
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Biosciences, MA, USA) and the volume was made up to 20 μl using nuclease free water in a 
sterile thin walled 0.2 ml PCR tube. The reaction mix was incubated in a Veriti Thermal Cycler 
(Applied Biosystems; Life Technologies Ltd, Paisley, UK) with the following protocol: 5 minutes 
at 25°C followed by 30 minutes at 42°C and then five minutes at 85°C. cDNA was stored at -
20°C until required. 
2.6.3 Quantitative real time polymerase chain reaction (qPCR) 
All qPCR assays were performed using the ABI Prism 7700 sequence detection system (Applied 
Biosystems; Life Technologies Ltd, Paisley, UK). The qPCR reaction was set up as a multiplex 
reaction in a 20 μl volume of an optical 96 well reaction plate and covered with optical 
adhesive film (both Applied Biosystems; Life Technologies Ltd, Paisley, UK). Each reaction 
contained 5 μl of diluted cDNA (1:10 with nuclease-free water), 10 μl of FastStart Universal 
Probe Master Mix (Roche Diagnostics Limited), 1 μl of 20x primer/probe of gene of interest, 1 
μl of 20x primer/probe endogenous control (Taqman, Applied Biosystems; Life Technologies 
Ltd, Paisley, UK) and 3 μl of nuclease free water. The primers and probes used are listed in 
Table 2.2. All reactions were run in triplicate and a water only (cDNA free) control was run for 
each primer-probe gene of interest. The samples were amplified using the standard relative 
quantification method using the following thermal-cycling conditions: enzyme activation at 
50C for 2 minutes, denaturation at 95C for 10 minutes followed by 40 cycles of amplification, 
at 95C for 15 s and extension at 60C for 1 minute.
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Table 2.2: List of Taqman primer/probe qPCR assays 
Gene Species Assay ID 
ICAM1 Mouse Mm00516023_m1 
SELE Mouse Mm00441278_m1 
CXCL1 Mouse Mm04207460_m1 
GAPDH Mouse Mm99999915_g1 
ANGPTL4 Human Hs01101127_m1 
CCL2 Human Hs00234140_m1 
CCL7 Human Hs00171147_m1 
CXCL1 Human Hs00236937_m1 
CXCL3 Human Hs00171061_m1 
CXCL8 Human Hs00174103_m1 
CXCL12 Human Hs03676656_mH 
ICAM1 Human Hs00164932_m1 
SELE Human Hs00174057_m1 
SPHK1 Human Hs01116530_g1 
VCAM1 Human Hs01003372_m1 
GAPDH Human 4310884E 
 
 
2.6.4 qPCR data analysis 
The delta-delta (ΔΔ) Ct method was used to quantify the relative levels of gene transcripts as 
previously reported (Livak and Schmittgen, 2001). Using amplification plots of fluorescent 
intensities generated by the ABI Prism 7700 sequence detection system, the threshold cycle 
(Ct) value was determined for each signal. Target gene values were normalised against an 
endogenous control (e.g. GAPDH) i.e. target Ct – endogenous control Ct.  The resultant value 
was then expressed relative to an appropriate reference sample which was assigned an 
arbitrary value of 1.  
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2.6.5 RNA sequencing (RNAseq)  
RNAseq was performed on 4 biological replicate pairs of HUVEC treated with S1P or vehicle 
control. Quality control check (RNA integrity number >7), library construction and sequencing 
was performed by BGI Tech Solutions (Hong Kong). RNA was hybridised to Illumina HiSeq 2000 
platform and data obtained using 10 M clean reads. Data were analysed in-house (see Section 
2.10). 
2.7 Protein analysis 
2.7.1 Western blotting 
Protein Extraction 
Suspension cells were pelleted by centrifugation at 200 g for five minutes. Cell pellets were 
washed in cold PBS and pelleted again in 1.5 ml eppendorfs prior to lysis. The medium of 
adherent cells was aspirated and the cells washed directly on the culture vessel with cold PBS 
prior to lysis. RIPA lysis buffer (140 mM NaCl, 10 mM Tris-HCl pH8, 1 mM EDTA, 1% Triton X-
100, 0.1% SDS, 0.1% Sodium deoxycholate (deoxycholic acid)) supplemented with 1 mM of 
activated sodium vanadate and 4% v/v protease inhibitor (cOmplete Tablets, EDTA-free; 
Roche Diagnostics Limited, UK) was added to the eppendorfs (suspension cells) or directly to 
the culture vessel (adherent cells) and left on ice for 30 minutes. The lysates were centrifuged 
in 1.5 ml eppendorfs at full speed at 4C for 15 minutes in a Heraeus Pico 17 Microcentrifuge 
(Thermo Fisher Scientific Inc, Waltham, MA, USA.). The protein supernatant was transferred 
to a new 1.5 ml eppendorf and stored at -20C until required.   
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Determination of Protein Concentration 
Protein concentration of samples was quantified using the Bio-Rad Protein Assay (Bio-Rad 
Laboratories Ltd., Hemel Hempstead, UK). Five standards of different concentrations of BSA 
(Sigma-Aldrich Ltd., Gillingham, UK): 0.1, 0.2, 0.3, 0.4 and 0.5 mg/ml were used. Each sample 
was diluted 1:10 with sterile distilled water. Ten µl of each standard and sample were plated 
in duplicate in a 96 well plate. Bio-Rad Protein Assay Reagent was diluted 1:5 in distilled water 
and 200 μl pipetted into each well. Absorbance was read on a Bio-Rad 680 microplate reader 
at 595 nm. The standards were used to plot a calibration curve from which the protein content 
of the samples was calculated. 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
10% SDS-PAGE gels were made as per Lab FAQs booklet (Roche Diagnostics Limited, UK). Gels 
were submerged in Tris-Glycine-SDS PAGE Buffer (Geneflow Ltd., Litchfield, UK) in a Mini 
Trans-Blot Cell tank (Bio-Rad Laboratories Ltd., Hemel Hempstead, UK).  Typically, 30 µg of 
protein lysates were mixed 1:4 v/v with 4x Laemmli sample buffer (Bio-Rad Laboratories Ltd., 
Hemel Hempstead, UK) and boiled at 95 C for 5 minutes to denature proteins. Samples were 
loaded into the wells of the pre made gel along with Spectra Multicolor Broad Range Protein 
ladder (Thermo Fisher Scientific Inc, Waltham, MA, USA). Proteins were separated at 130 V 
for 1.5-2 hours depending on the size of the protein of interest.  
Transfer of protein 
Proteins were transferred from the gel to a polyvinylidene fluoride (PVDF) membrane using 
the ready-to-use Trans-Blot Turbo Mini PVDF Transfer Packs (Bio-Rad Laboratories Ltd., Hemel 
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Hempstead, UK) set up in Trans-Blot Turbo Transfer System (Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK). Proteins were transferred using the built in program of 1.3A, 25V for 7 
minutes.  
 
Immunoblotting 
Non-specific protein binding was blocked by incubating the membrane for 1 hour at room 
temperature on a shaker in 5% dried milk dissolved in Tris buffered saline-0.1 % Tween-20 
(TBST). Membranes were incubated with primary antibodies diluted to the appropriate 
concentrations (Table 2.3) in 5% w/v BSA/TBST on a rocker overnight at 4C. The following 
day, membranes were washed 3 times, each for a total of 10 minutes, on a shaker in TBST 
prior to incubation for 1 hour in the appropriate HRP-conjugated secondary IgG antibodies 
Table 2.3: List of antibodies used  
Antibody Species Application Company Dilution 
SPHK1 Rabbit Western blotting Cell signalling 1:1000 
Phospho-SPHK1 (Ser-225) Rabbit Western blotting ECM bioscience 1:1000 
PARP Rabbit Western blotting Cell signalling 1:1000 
ERK Rabbit Western blotting Cell signalling 1:1000 
Phospho-ERK (Thr202/Tyr204) Rabbit Western blotting Cell signalling 1:1000 
SPHK1 Rabbit IHC Cell signalling 1:100 
S1PR1 (H-60) Rabbit IHC Santa cruz 1:600 
S1PR2 Rabbit IHC Sigma-Aldrich 1:200 
S1PR3 Rabbit IHC MyBioSource 1:600 
CD15 (C3D-1) Mouse IHC Dako 1:400 
CD68 (PG-M1) Mouse IHC Dako 1:200 
CD31 Rabbit IHC Abcam 1:200 
CD45-Pacific Blue (2D1) Mouse Flow cytometry Ebioscience 1:100 
CD144-APC (16B1) Mouse Flow cytometry Ebioscience 1:100 
CD31-PE (WM-59) Mouse Flow cytometry Ebioscience 1:100 
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(Dako UK Ltd., Cambridgeshire, UK) which were diluted 1:1000 in 5% w/v milk/TBST. The 
membranes were washed again 3 times, each for a total of 10 minutes, on a shaker in TBST. 
Proteins were visualised using Bio-Rad Clarity Western enhanced chemiluminescence (ECL) 
(Bio-Rad Laboratories Ltd., Hemel Hempstead, UK). Membranes were incubated with ECL 
mixture for 1 minute and then the excess liquid was drained off. The membrane was placed 
inside a plastic covering and developed on the ChemiDoc MP (Bio-Rad Laboratories Ltd., 
Hemel Hempstead, UK). Densitometry analysis was performed using ChemiDoc software.  
Following the detection of the protein of interest, membranes were washed 3 times, each for 
a total of 10 minutes, in TBST and then re-probed for β-tubulin-HRP (Abcam, Cambridge, UK) 
diluted 1:1000 in 5% w/v milk/TBST for 1 hour at room temperature. Membrane was 
developed as described. 
2.7.2 Immunohistochemistry (IHC) 
Preparation of cells grown on microscope slides 
HUVEC were grown on multi-spot coated microscope slides and then washed and fixed by 
submerging the slide in PBS for 2 minutes and 10% formal-saline solution for 10 minutes. 
Slides were then air-dried and stored at -20˚C until required.  
Prepared slides of fixed HUVEC/HEK293 cells were thawed and then rinsed in running tap 
water for five minutes. The endogenous peroxidase activity was blocked by placing the slides 
in 0.3% hydrogen peroxidase (Sigma-Aldrich Ltd., Gillingham, UK) for 15 minutes. 
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Preparation of tissue sections 
Paraffin-embedded blocks of DLBCL patient biopsy samples and reactive tonsil were obtained 
from the Queen Elizabeth Hospital, Birmingham, UK, with full ethical approval (No. RG_08-
103). Paraffin embedded blocks of mouse tissue samples were processed by the Royal 
Orthopaedic Hospital (University of Birmingham). Sections were cut to a thickness of 4 µm 
onto X-tra Adhesive micro slides (Surgipath Europe, Peterborough, UK). The sections were de-
waxed by immersing the slides in Histoclear (National Diagnostics, Hessel, UK) for 10 minutes 
and then rehydrated by immersing in 100% ethanol for 5 minutes (Sigma-Aldrich Ltd., 
Gillingham, UK) followed by tap water for a further 5 minutes. The endogenous peroxidase 
activity was blocked by placing the slides in 0.3% hydrogen peroxidase (Sigma-Aldrich Ltd., 
Gillingham, UK) for 15 minutes. 
Antigen Retrieval 
One litre of citrate buffer containing: 1.26 g sodium citrate, 0.25 g citric acid, 800 ml distilled 
water, pH adjusted to pH 6.0 with 0.1 M sodium hydroxide, was boiled in a glass beaker for 10 
minutes on full power in a microwave prior to immersing the slides. The beaker containing the 
slides was then heated for 10 minutes at moderate power and then 10 minutes at low power. 
The buffer was then allowed to cool (approximately 30 minutes) before the slides were 
removed and rinsed in running tap water.  
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Detection of antigen  
Following antigen retrieval, slides were placed in a metal microscope slide staining tray 
(Richardsons of Leicester Ltd., Leicester, UK) and washed with PBS-Tween-20 (0.1%) (PBST) for 
5 minutes.   
For human sections and fixed HUVEC/HEK293 cells: to reduce non-specific 
background staining, samples were blocked using 5X casein blocking solution (Vector 
Laboratories Ltd., Peterborough, UK) and incubated with diluted primary antibody in PBST 
overnight at 4C (Table 2.3). Samples were washed with PBST for 5 minutes and incubated 
with DAKO Envision secondary antibody (Dako UK Ltd., Cambridgeshire, UK) for 30 minutes at 
room temperature. Samples were washed again with PBST for 5 minutes. Samples were 
incubated with diaminobenzidine (DAB) (Vector laboratories Ltd,. Peterborough, UK) which is 
converted to an insoluble brown product by the antigen-bound peroxidases allowing for 
visualisation of antigens bound to antibody. 
For mouse sections: For CD15 and CD68 antibodies the M.O.M (mouse on mouse) 
detection kit (Vector laboratories Ltd,. Peterborough, UK) was used according to the 
manufacturer’s protocol to reduce endogenous mouse Ig staining. For the SPHK1 and CD31 
antibodies, the same process was carried out as the staining for human sections (above) but 
with incubation with anti-rabbit HRP-conjugated secondary IgG antibody diluted 1:200 in PBST 
(Dako UK. Ltd).  
All sections were rinsed with distilled water and then counterstained with Mayer’s 
haematoxylin (Sigma-Aldrich Ltd., Gillingham, UK) for 60 s and then rinsed again under running 
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warm tap water for 2 minutes. Stained sections were dehydrated by immersion in 100% 
ethanol for 5 minutes followed by Histoclear for 10 minutes and mounted with cover slips 
using DPX mounting medium (Sigma-Aldrich Ltd., Gillingham, UK) for microscopic 
examination. Slides were assessed by Dr Maha Ibrahim (University of Birmingham). 
2.7.3 Flow cytometry 
For flow cytometry, adherent cells were detached from the culture vessel by incubation with 
StemPro Accutase Cell Dissociation Reagent (Gibco, Life Technologies Ltd, Paisley, UK). Cells 
were counted and 1 x 106 cells pipetted into flow cytometry tubes for each stain required. 
Additionally, a tube of compensation beads (BD Biosciences, USA) was used for each antibody 
stain, each containing one drop of the relevant anti-species Ig and negative control.  Cells and 
compensation beads were washed with 1% v/v FBS/PBS and then pelleted by centrifugation 
at 200 g for 5 minutes. The pellets were resuspended in 100 μl of 1% v/v FBS/PBS with 
antibody at the appropriate concentration (Table 2.3) and incubated at 4C for 15 minutes in 
the dark. Following this, cells and compensation beads were washed in 1% v/v FBS/PBS and 
then fixed by resuspension in 200 µl of 1% paraformaldehyde. Cells were analysed using a BD 
LSR II Cell Analyzer (BD Biosciences, USA) and the data were analysed using Flowjo software 
(TreeStar Inc.). 
2.7.4 Enzyme-linked immunosorbent assay (ELISA)  
The production of chemokines by HUVEC was measured using a commercially available ELISA 
kit (DuoSet ELISA Development Systems; R&D Systems, Bio-Techne Ltd. Abingdon, UK.). For 
this assay, HUVEC were grown in normal growth conditions on 6 well dishes until they reached 
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confluency. The HUVEC were washed twice with PBS and culture media changed to M199 
supplemented with 5% v/v FBS and 1% v/v P/S, to deplete the HUVEC of ECGS for 16 hours. 
The culture media was then changed for fresh M199 supplemented with 5% v/v FBS and 1% 
v/v P/S 1 hour prior to the treatment with S1P. S1P or vehicle control was then added directly 
to the medium which served as a 0 hours time point. HUVEC which received two S1P 
stimulations received the second S1P treatment at 6 hours. At 12 hours, the conditioned 
medium was collected and stored at -20C until required. The ELISA was performed in 
accordance with the manufacturer’s protocol and absorbance read at 450 nm.  A calibration 
curve was calculated from the standards supplied in the kit using an online tool 
(www.elisaanalysis.com), which was then used to calculate the concentrations of the 
chemokines in the samples. 
2.8 Migration assay 
A transwell (Corning, Sigma-Aldrich Ltd., Gillingham, UK) was prepared by the addition of 600 
μl of RPMI-1640 supplemented with 1% v/v FCS and chemokine (CXCL1 or MCP1; PeproTech, 
USA) or vehicle at the relevant concentration to the lower wells of a 24 well plate. 1 x 105 THP-
1 cells or human CD14+ monocytes (provided by Tracey Perry) in 100 μl of RPMI-1640 
supplemented with 1% v/v FCS were transferred into the transwell inserts (porse size 3 
microns; Corning, Sigma-Aldrich Ltd., Gillingham, UK). Each treatment was run in triplicate. 
After 4 hours, transwell inserts were removed and all cells in the bottom wells pelleted and 
resuspended in 200 ul of 1% v/v FBS/PBS. Cells in each sample were counted on a BD LSR II 
Cell Analyzer for 60 s. 
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2.9 A20 syngeneic mouse model 
A20 cells were injected at 3 x 106 cells/mouse intravenously into 6-9 week old female BALB/c 
mice ( , USA) (carried out by ) (Home office 
ethical approval, project no. PPL70_8280). At day 28, mice were killed by cervical dislocation 
and the spleens and livers were collected in RPMI-1640 (carried out by  
). A portion of liver and spleen was fixed in 10% formalin. Histology services at 
the Royal Orthopaedic Hospital, University of Birmingham, embedded the samples in paraffin 
wax and provided haematoxylin and eosin (H&E) stained sections. H&E sections were analysed 
by pathologist Dr Maha Ibrahim (University of Birmingham).  
2.10 Statistical and bio-informatic analysis 
Statistical analysis of data was performed using Graphpad Prism 7 software.  
The reanalysis of published RNAseq data was performed by Dr Robert Hollows (University of 
Birmingham). The data for 32 ABC DLBCL and 54 GCB DLBCL were downloaded from the 
controlled access area of NIH database of genotypes and phenotypes (dbGap; 
http://www.ncbi.nlm.nih.gov/gap) using accession code phs000532.v5.p2 (Morin et al., 
2013). The data for 4 GC B cell samples were downloaded from the Gene Expression Omnibus 
(GEO; http://www.ncbi.nlm.nih.gov/geo/) (accession GSE45982). The data for all samples 
were aligned to the hg19 human genome using Rsubread aligner (Liao et al., 2013) and 
assigned to individual genes using the featureCounts function. Read counts were then 
normalized between samples and converted to counts-per-million (CPM) reads for each gene 
using the edgeR package  in R (Robinson et al., 2010). 
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The analysis of the S1P-treated HUVEC RNAseq data was performed by Dr Wenbin Wei 
(University of Birmingham). The same methodology was used as above to generate CPM 
values. Differentially expressed genes were identified using edgeR with p<0.05 and read CPM 
>1 in at least half of the sample list. 
The reanalysis of microarray data was performed by Dr Wenbin Wei (University of 
Birmingham). The data for 11 DLBCL and 10 GC B cell samples was downloaded from the GEO 
(accession GSE12453) (Brune et al., 2008) and analysed using the MAS5 algorithm of the 
Affymetrix Expression Console to generate expression levels for each probe set (GCOS Signal). 
The MAS5 TGT was set to 100.
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CHAPTER THREE 
INVESTIGATING THE EFFECTS OF SPHK1 
OVEREXPRESSION IN DLBCL AND DEFINING AN S1P 
GENE SIGNATURE PRESENT IN PRIMARY TUMOURS 
|69 
 
3.1 Abstract 
S1P is a small bioactive lipid, which through cellular signalling can induce many biological 
effects such as growth, survival and differentiation (Pyne and Pyne, 2000). In particular S1P 
has been shown to regulate vascular functions and angiogenesis. SPHK1, the main enzyme 
responsible for producing S1P, has been described as an oncogene and shown to be 
overexpressed in many cancers including NHL (Bayerl et al., 2008, Xia et al., 2000). However, 
our understanding of the contribution of SPHK1-S1P signalling to the pathogenesis of DLBCL, 
including its potential role in angiogenesis, remains unexplored.  
In this chapter I show that SPHK1 is overexpressed in DLBCL and that SPHK1 expression 
correlates with the expression of known tumour-associated angiogenic genes. I also describe 
here the characterisation of HUVEC as a model which can be used to define an S1P-associated 
gene signature in primary DLBCL.
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3.2 Results 
3.2.1 SPHK1 is overexpressed in primary DLBCL and DLBCL cell lines 
I first studied the expression of SPHK1 protein in tumour biopsy sections from 39 DLBCL 
patients. These samples were obtained from the Human Bioresource Resource Centre and the 
diagnosis of DLBCL was independently confirmed by three pathologists prior to analysis. To 
detect SPHK1 protein, I performed IHC. One case was excluded due to tissue being extensively 
crushed. Of the remaining 38 cases I observed SPHK1 staining in the tumour cells of 36/38 
cases (Figure 3.1A). In one of the two negative cases, I observed staining in the squamous 
epithelium which served as an internal positive control. The other negative case was excluded 
due to the lack of an internal positive control (Appendix 1). As a consistent internal positive 
control was not present in all cases, I was unable to accurately assess the level of protein and 
determine whether SPHK1 was overexpressed. To overcome this I used available gene 
expression datasets to determine the level of SPHK1 mRNA in DLBCL cases compared to 
normal germinal centre B (GC B) cells (Brune et al., 2008, Morin et al., 2011). First, the 
reanalysis of a published RNAseq dataset showed a statistically significant increase in SPHK1 
expression in both ABC DLBCL (n=32) and GCB DLBCL (n=54) compared to normal GC B cell 
samples (n=4) (p<0.0001, for both comparisons) (Figure 3.1B). Furthermore, the reanalysis of 
a published microarray dataset also revealed a statistically significant increase in SPHK1 
expression when 11 primary DLBCL samples (subtypes unknown) were compared to 10 GC B 
cell samples (p=0.002) (Figure 3.1C)
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Figure 3.1: SPHK1 expression in primary DLBCL. (A) Representative IHC stains for SPHK1 expression. 
SPHK1 is expressed in normal GC cells of a tonsil (top left). SPHK1 negative DLBCL case 1/37 (top 
right). Two representative SPHK1 positive DLBCL cases from 36/37 (bottom panel). GC = germinal 
centre, MZ = mantle zone. (B) The reanalysis of RNAseq data shows a statistically significant increase 
in SPHK1 expression in 32 cases of ABC DLBCL and 54 cases of GCB DLBCL compared to 4 normal 
GCB cell samples. (C) Reanalysis of a published microarray dataset shows a statistically significant 
increase in SPHK1 expression in 11 primary DLBCL samples compared to 10 GC B cell samples. 
Students T-test. 
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Next, I compared the expression of SPHK1 mRNA in 9 DLBCL cell lines with that in CD10+ GC B 
cells isolated from three donors (provided by Dr Vrzalikova). SPHK1 expression was detected 
in all cell lines and, with the exception of SUDHL4, expression was the same or higher than in 
all three GC B cell samples (Figure 3.2A). Activation of SPHK1 and translocation to the plasma 
membrane where its substrate resides is mediated by phosphorylation at Serine 225 (Pitson 
et al., 2003b). Previous studies from our lab, (Abdullah et al; unpublished), have shown that 
available phospho-specific SPHK1 antibodies do not work in IHC. To ascertain the 
phosphorylation of SPHK1 in DLBCL cells I performed immunoblotting of the available DLBCL 
cell lines (Figure 3.2B). Consistent with the results of the qPCR analysis, I observed expression 
of SPHK1 in all cell lines. I detected phosphorylated SPHK1 in all cell lines, confirming the 
presence of the activated form of SPHK1. 
3.2.2 SPHK1 expression is associated with angiogenic functions in primary DLBCL  
Next, I identified a subset of genes that were co-expressed with SPHK1 in primary DLBCL using 
data provided by Dr Reuben Tooze (University of Leeds) in which a meta-analysis of ten 
different DLBCL gene expression datasets, including more than 2000 cases of whole tumour 
primary DLBCL, had been performed. Within each of the ten gene expression datasets, the 
Spearman’s rank correlation was calculated for the expression of SPHK1 against all other genes 
individually (n=20,121). The resultant p values and correlations for each gene from all datasets 
were merged by taking the median values (Care et al., 2015). I identified 2236 genes that were 
significantly positively correlated, and 1658 genes that were significantly negatively 
correlated, with SPHK1 expression in primary DLBCL (p<0.05). Importantly, this gene signature 
included genes expressed from cells within the tumour microenvironment as well as the 
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tumour cells as it was generated using data from whole tumour biopsies. Using an online gene 
functional classification tool, DAVID (https://david.ncifcrf.gov/) (Dennis et al., 2003),  I 
performed gene ontology analysis of the genes correlated with SPHK1 expression. This 
analysis identified a significant enrichment of vasculature related ontology terms in the 
significantly positively correlated gene set (Figure 3.3).   
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Figure 3.2: SPHK1 expression in DLBCL cell lines. (A) qPCR analysis for the expression of SPHK1 in 
DLBCL cell lines (dark grey bars) and GC B cell samples (light grey bars). Data are presented as  
2
-ΔΔCT 
and relative to one GCB sample. (B) Immunblotting analysis of DLBCL cell lines for 
phosphorylated and total SPHK1 (pSPHK1, tSPHK1, respectively). β-tubulin is a loading control. *= 
EBV+ cell line. 
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Figure 3.3: SPHK1 expression is associated with angiogenic functions in primary DLBCL. Gene 
ontology (GO) analysis of genes positively associated with the expression of SPHK1 in primary DLBCL 
ordered by p value. Analysis reveals GO terms associated with blood vessel function (red arrows). 
Dark grey bars represent the observed percentage of upregulated genes in a particular GO category. 
Light grey bars represent the expected percentage of  upregulated genes in a particular GO category. 
P value of each term was determined using Fisher’s exact test. 
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To provide further confirmation that angiogenesis related genes were enriched in the set of 
genes co-expressed with SPHK1 in DLBCL, I took advantage of the availability of a published 
‘tumour vascular gene signature.’ This tumour vascular signature was generated from an 
integrative meta-analysis of more than 1000 primary human cancers and is comprised of 
genes the expression of which jointly correlates with that of many angiogenic genes or 
endothelial cell specific genes (Masiero et al., 2013). Using only genes present on both 
platforms (n= 17851; Table 3.1), I compared the genes significantly correlated with SPHK1 
expression in primary DLBCL to this tumour vascular gene signature (Table 3.2). This analysis 
revealed that genes positively correlated with SPHK1 expression in primary DLBCL were 
significantly enriched for tumour vasculature signature genes (chi-square=560.18, odds 
ratio=7.9, p<0.0001; Table 3.3; Figure 3.4), whereas genes negatively correlated with SPHK1 
in primary DLBCL were significantly depleted for tumour vascular signature genes (chi-
square=14.42, odds ratio=0.37, p<0.0001; Table 3.3; Figure 3.4). Taken together, these results 
suggest that the overexpression of SPHK1, which would be expected to lead to the increased 
production of extracellular S1P, could promote angiogenesis in DLBCL.  
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Table 3.1: Number of genes positively and negatively correlated with SPHK1 expression in primary 
DLBCL and present in the tumour vascular signature including those used in the enrichment 
analyses. 
 
 
Total 
Number 
Number of genes used in enrichment analysis (present 
on both DLBCL-SPHK1 correlated genes dataset and 
tumour vascular signature genes dataset n=17851) 
Genes positively correlated with 
SPHK1 expression in primary DLBCL 2236 2150 
Genes negatively correlated with 
SPHK1 expression in primary DLBCL 1658 1517 
Tumour vascular signature genes 471 471 
 
Table 3.2: Numbers of genes in the tumour vascular signature that were also found to be either 
positively or negatively correlated with the expression of SPHK1 in primary DLBCL 
 
  
Tumour Vascular Signature Genes 
(n=471) 
Genes positively correlated with SPHK1 expression in primary 
DLBCL (n=2150) 235 
Genes negatively correlated with SPHK1 expression in primary 
DLBCL (n=1517) 16 
 
Table 3.3: Chi-square test of the overlap between genes correlated with the expression of SPHK1 
in primary DLBCL and those present in the tumour vascular signature 
 
Observed 
(O) 
Expected 
(E) O-E 
Chi 
square 
Odds 
Ratio P-Value 
Tumour vascular signature genes 
and genes positively correlated 
with SPHK1 expression in primary 
DLBCL 
235 56.73 178.27 560.18 7.9 <0.0001 
Tumour vascular signature genes 
and genes negatively correlated 
with SPHK1 expression in primary 
DLBCL 
16 40.03 -24.03 14.42 0.37 <0.0001 
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Figure 3.4: Genes co-expressed with SPHK1 in primary DLBCL are enriched for tumour vascular 
signature genes. Venn diagrams showing the overlap between genes positively or negatively correlated 
with SPHK1 in primary DLBCL (dark grey and blue circles respectively) with tumour vascular signature 
genes (light grey circles). Genes positively correlated with the expression of SPHK1 in primary DLBCL 
were significantly enriched for tumour vascular signature genes (chi square=560.18, odds ratio=7.6, 
p<0.0001). Genes negatively correlated with SPHK1 expression in primary DLBCL were significantly 
depleted for tumour vascular signature genes (chi-square=14.42, odds ratio=0.3, p<0.0001,) OR= odds 
ratio. 
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3.2.3 Establishing HUVEC as a model system to study the effects of S1P on DLBCL-associated 
endothelial cells 
To further explore the potential impact of S1P on angiogenesis in DLBCL, I wanted to establish 
an in vitro model which would allow me to more directly study the impact of S1P signalling on 
the transcription of endothelial cells and, in turn, the extent to which this transcriptome could 
be observed in SPHK1 overexpressing DLBCL. To do this I used HUVEC, which are primary cells 
derived from the endothelium of veins from the umbilical cord that are extensively used as an 
in vitro endothelial cell model. 
In this section I describe the isolation and characterisation of HUVEC, including the expression 
of S1P receptors, and show that this model is a useful one with which to study S1P activated 
signalling and resulting expression of angiogenesis-associated genes. 
1. Identification and characterisation of HUVEC 
HUVEC were isolated from the umbilical cords of four donors using collagenase treatment. As 
expected the cells were homogenous in morphology and exhibited a cobblestone growth 
pattern typical of endothelial cells (Figure 3.5A). Flow cytometry showed that over 97% of 
isolated cells were positive for CD31 and CD144, which are established biomarkers of 
endothelial cells, and negative for the leukocyte common antigen, CD45, indicating high purity 
without contamination from peripheral blood cells (Figure 3.5B).
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Side Scatter 
Figure 3.5: Purity of isolated HUVEC. (A) Representative image of cultured HUVEC showing cobblestone 
morphology typical of endothelial cells. (B) Isolated HUVEC samples were analysed by flow cytometry for 
expression of CD31, CD144 and CD45 in comparison to unstained cells (solid grey peak) to assess purity. Cells 
were gated by forward scatter and side scatter (top panel) to include all cells in the analysis. All four HUVEC 
samples were >97% positive for the endothelial markers CD31 and CD144 and negative for the leukocyte 
common antigen CD45. 
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2. S1P receptor expression in HUVEC is representative of that observed in DLBCL-associated 
endothelial cells 
I next wanted to characterise the expression of the three major S1P receptors S1PR1, S1PR2 
and S1PR3 in the tumour-associated endothelial cells of primary DLBCL and to ascertain if 
HUVEC recapitulate this expression profile. I first confirmed the specificity of the antibodies I 
was using by showing strong staining of S1PR1, S1PR2 and S1PR3 in plasmid transfected 
HEK293 cells but not in empty vector control transfected HEK293 cells (Figure 3.6). IHC with 
these antibodies revealed that the tumour-associated endothelial cells expressed S1PR1 in all 
cases of DLBCL (n=36). In contrast, S1PR2 was absent in endothelial cells in 35 cases, despite 
the strong expression of S1PR2 in red blood cells. Of the 36 cases stained for S1PR3, 17 cases 
were excluded due to the lack of an internal positive control (tumour cell positivity or 
squamous epithelial cell positivity). Of the remaining 19 cases S1PR3 was not expressed in the 
tumour-associated endothelial cells (Figure 3.7; Appendix 1).  
I next characterised the expression of S1P receptors in isolated HUVEC. Figure 3.8 shows that 
S1PR1 was highly expressed whereas S1PR2 and S1PR3 protein was not detectable in HUVEC. 
Mantle zone, germinal centres and squamous epithelium of tonsil were used as positive 
controls (Figure 3.8).    
Taken together, these results show that HUVEC are a suitable model in which to study the S1P 
signalling of DLBCL-associated endothelial cells. 
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Figure 3.6: Validation of the specificity of S1P receptor antibodies. HEK293 cells were 
transfected with vector only control or S1P receptor expression plasmid. Receptor expression 
plasmid transfected cells shows strong specific staining compared to empty vector control 
transfected cells. 
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Figure 3.7: DLBCL-associated endothelial cells express S1PR1 but not S1PR2 or S1PR3. 
Representative IHC images of staining for S1PR1, S1PR2 and S1PR3 in DLBCL, endothelial cells were 
positive for S1PR1, but negative for S1PR2 and S1PR3 (black arrows). Bottom left shows S1PR3 
positive tumour cells.  
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Figure 3.8: HUVEC express S1PR1, but not S1PR2 or S1PR3. S1P receptor expression was 
characterised by IHC. Tonsil was used as a positive control and showed S1PR1 expression in the 
mantle zone (MZ), S1PR2 expression in the germinal centre (GC) and S1PR3 expression in the 
squamous epithelium (SE). 
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3. S1P activates signalling pathways and the transcription of angiogenic genes in HUVEC 
The cell culture medium of HUVEC contains commercially available endothelial cell growth 
supplement which contains angiogenic growth factors such as VEGF and FGF. As these growth 
factors could decrease the sensitivity of any signalling effects from S1P treatment, I first 
studied the effects of the removal of these growth factors from the cell culture medium. One 
possible outcome could be increased apoptosis. To study the effects of removal of these 
growth factors on cell survival I performed immunoblotting against poly ADP-ribose 
polymerase (PARP) as PARP cleavage by caspases is a marker of apoptosis. As a positive 
control, I used cells which had been serum starved for 24 hours. As expected I detected 
cleaved PARP (89kDa) in these cells (Figure 3.9). However, I did not detect cleaved PARP 
following the removal of growth factors from the media of HUVEC (Figure 3.9). 
As the activation of ERK has been shown to be important for angiogenic functions in HUVEC 
induced by factors such as VEGF, I also studied the effects of growth factor removal on ERK 
activation (Rousseau, 1997). Removal of growth factors reduced the levels of phosphorylated 
ERK (pERK) (Figure 3.10).  
Based on the results of these experiments I chose to deplete the HUVEC of endothelial cell 
growth supplement for 16 hours prior to S1P stimulation so as to increase the sensitivity of 
any observed S1P signalling effects.
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Figure 3.9: Detection of PARP in HUVEC following growth factor depletion. HUVEC were cultured 
in media either in the absence or presence of endothelial growth supplement (growth factors) and 
harvested at the indicated time points. Immunoblotting revealed no detectable PARP cleavage 
(89kDa) in cells cultured in media containing or not containing growth factor supplements at all time 
points. β-tubulin confirmed equal loading of samples. Data shown are representative of three 
independent experiments from three different HUVEC donors. 
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Figure 3.10: Detection of ERK in HUVEC following growth factor depletion. HUVEC were cultured 
in media either in the absence or presence of endothelial growth supplement (growth factors) and 
harvested at the indicated time points. Immunoblotting revealed higher levels of pERK in cells grown 
in media containing growth factor supplement compared to those grown in media without growth 
factor supplement. β-tubulin confirmed equal loading of samples. Data shown are representative of 
two independent experiments from two different HUVEC donors. 
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Next, I investigated ERK activation following the treatment of HUVEC with S1P. I performed 
immunoblotting against pERK on HUVEC treated with various concentrations of S1P for 5 
minutes. S1P activated ERK at all concentrations reaching a maximum at 0.5 µM (Figure 3.11). 
For all subsequent stimulations I treated cells with 0.5 µM S1P. 
Having shown that S1P activates ERK signalling in HUVEC, I next explored whether this is 
associated with changes in gene transcription in these cells. I chose three known target genes 
of S1P in endothelial cells, ICAM1, CXCL8 which encodes IL8, and SELE which encodes E-
Selectin (Lin et al., 2006, Shimamura et al., 2004). I showed using qPCR that the expression of 
all three genes was upregulated in HUVEC from four different donors following treatment with 
S1P for 4 hours (Figure 3.12).
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Figure 3.11:  S1P treated HUVEC activate ERK in a dose dependent manner.  HUVEC were treated 
with S1P at the indicated concentrations and harvested at 5 minutes. Immunoblotting revealed the 
dose dependent activation of ERK by S1P shown by increased levels of pERK compared to control. 
β-tubulin confirmed equal loading of samples. Data shown are representative of four independent 
experiments from four different HUVEC donors.  
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Figure 3.12:  Upregulation of known S1P target genes in HUVEC. qPCR analysis shows the 
upregulation of ICAM1 (A), SELE (B) and CXCL8 (C) in HUVEC treated with S1P (dark grey bars) relative 
to untreated cells (light grey bars).  Shown are the results from four separate donors (HUVEC 1-4). 
Samples were analysed in triplicate and are presented as 2
-ΔΔCT 
values in comparison to 
corresponding control.  
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3.2.4 Optimisation of conditions and time point to study global gene expression changes in 
S1P treated HUVEC 
S1P-mediated signalling pathway activation is transient in HUVEC 
Having shown that HUVEC can be used to study the effects of S1P on the transcription of 
endothelial cells, I next wanted to optimise the conditions under which I could study global 
gene expression.  The activation of ERK by S1P was further examined by treating HUVEC with 
S1P for various times. Fig 3.13 shows that the initial and rapid induction of ERK 
phosphorylation by S1P is transient, reaching a maximum at 5 minutes and declining back to 
basal levels from 1 hour.   
Upregulation of S1P target genes following S1P treatment is transient 
To choose an appropriate time point to study the global gene expression in S1P treated 
HUVEC, I performed a time course on S1P treated HUVEC using the expression of three S1P 
target genes, ICAM1, CXCL8 and SELE, as a read out. qPCR showed that the S1P-mediated 
upregulation of these genes is transient, with highest upregulation observed at 3h for CXCL8 
and 4h for ICAM1 and SELE (Figure 3.14).
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Figure 3.13:  Activation of ERK is rapid and transient following S1P treatment of HUVEC. 
HUVEC were treated with S1P for the indicated time periods. Immunoblotting revealed that the 
activation of ERK by S1P is rapid, reaching maximum levels at 5 minutes and declining back to 
basal levels by 1 hour.  β-tubulin confirmed equal loading of sample. Data shown are 
representative of four independent experiments from four different HUVEC donors.  
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Figure 3.14: Time course of S1P target genes in HUVEC. qPCR analysis for the expression of CXCL8 
(A), ICAM1 (B) and SELE (C) in HUVEC treated with S1P at indicated time points (light grey bars) 
relative to vehicle treated cells (dark grey bars). Analysis reveals the transient upregulation of genes 
reaches maximum expression levels for CXCL8 at 3 hours and ICAM1 and SELE at 4 hours. Samples 
were analysed in triplicate and are presented as 2
-ΔΔCT  
values in comparison to corresponding 
control.  
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3.2.5 Identification of S1P target genes in HUVEC 
I chose 4h as the optimum time point for a global gene expression analysis following S1P 
treatment of HUVEC. The upregulation of ICAM1, CXCL8 and SELE was confirmed in HUVEC 
from four different donors by qPCR prior to RNA sequencing analysis performed by BGI Tech 
Solutions (Hong Kong) (Figure 3.15). Following quality control checks, RNA was hybridised to 
Illumina Hiseq 2000 platform and data obtained using 10M reads per sample.  
RNAseq data were mapped to 25,702 Entrez genes using criteria set out in the Materials and 
Methods (Section 2.10). Differentially expressed genes were identified using edgeR with p < 
0.05 and read CPM > 1 in at least half of the samples. I found that S1P treatment of HUVEC 
was followed by the upregulation of 116 genes and the downregulation of 126 genes 
(Appendix 2). 
3.2.6 Validation of S1P target genes identified in HUVEC 
The RNAseq analysis identified the upregulation of ICAM1 and SELE, two genes I had 
previously shown to be upregulated by S1P (Figure 3.15). However, CXCL8 was not identified 
as an S1P target gene by RNAseq analysis. Fig 3.16 shows that RNAseq analysis revealed the 
upregulation of CXCL8 in 2 out of the 4 pairs of samples. As this gene has previously been 
identified as an S1P endothelial cell target gene and as I confirmed the upregulation of IL8 
protein in HUVEC following S1P treatment (shown later; Figure 4.11) I chose to include CXCL8 
in all subsequent analyses. 
I used qPCR to validate the upregulation of three additional genes identified by RNAseq 
analysis which encode proteins of varying functions. These included the genes for SPHK1 itself, 
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the transmembrane adhesion molecule vascular cell adhesion protein-1 (VCAM1), the 
secreted chemokine C-C Motif ligand 2 (CCL2) and the glycosylated secreted protein 
angiopoietin-like 4 (ANGPTL4) (Figure 3.17). 
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Figure 3.15: Validation of the upregulation of S1P target genes in HUVEC used for RNAseq analysis. 
qPCR analysis confirms the upregulation ICAM1 (A), SELE (B) and CXCL8 (C) in HUVECs treated with 
S1P for 4h (dark grey bars) relative to untreated cells (light grey bars) from four different donors 
(HUVEC 1-4). Samples were analysed in triplicate and are presented as 2
-ΔΔCT  
values in comparison to 
corresponding control.  
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Figure 3.16: The RNAseq CPM values for CXCL8 in the four HUVEC control and S1P treated samples. 
The CPM values from the RNAseq analysis in four HUVEC samples treated with S1P (dark grey bars) 
and corresponding vehicle treated control (light grey bars). This shows that CXCL8 was detected as 
upregulated in two out of the four pairs of HUVEC. 
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Figure 3.17: Validation of genes upregulated in HUVEC by S1P treatment identified by RNAseq 
analysis. qPCR was used to measure the relative quantity of CCL2 (A), SPHK1 (B), VCAM1 (C) and 
ANGPTL4 (D) in HUVECs treated with S1P for 4h (dark grey bars) relative to untreated cells (light 
grey bars) from four different donors (HUVEC 1-4). Samples were analysed in triplicate and are 
presented as 2
-ΔΔCT  
values in comparison to corresponding control.  
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3.2.7 The S1P-endothelial cell gene signature is enriched in primary DLBCL 
The genes differentially regulated in HUVEC following S1P stimulation constitute a potential 
S1P signalling endothelial cell signature. To determine if this signature is detectable in primary 
DLBCL, I used those genes that I previously showed to be correlated with SPHK1 expression in 
primary DLBCL (Section 3.2.2). Using only genes present on both platforms (Table 3.4), I 
compared the genes that were significantly correlated with SPHK1 expression in primary 
DLBCL with the genes regulated by S1P in HUVEC (Table 3.5). This analysis revealed that genes 
positively correlated with the expression of SPHK1 in primary DLBCL were significantly 
enriched for genes upregulated, but not genes downregulated, by S1P in HUVEC (chi-
square=52.78, odds ratio =4.55, p<0.0001; chi-square=0.51, odds ratio =0.78, p=0.48; 
respectively. Table 3.6; Figure 3.18). It also revealed that genes negatively correlated with the 
expression of SPHK1 in primary DLBCL were significantly enriched for genes downregulated, 
but not genes upregulated, by S1P in HUVEC (chi-square=15.27, odds ratio =2.58, p<0.0001; 
chi-square=0.59, odds ratio =0.71, p=0.44; respectively. Table 3.6; Figure 3.18). These results 
provide strong evidence that an S1P-endothelial cell gene signature is present in SPHK1 
expressing primary DLBCL.
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Table 3.4.Number of genes positively and negatively correlated with SPHK1 expression in primary 
DLBCL and genes upregulated and downregulated by S1P in HUVEC including those used in the 
enrichment analyses. 
 
 Total Number 
Number of genes used in enrichment analysis 
(present on both DLBCL-SPHK1 correlated genes 
dataset and S1P regulated HUVEC genes dataset 
n=17446) 
Genes positively correlated with 
SPHK1 expression in primary DLBCL 2236 2145 
Genes negatively correlated with 
SPHK1 expression in primary DLBCL 1658 1537 
Genes upregulated by S1P in HUVEC 117 93 
Genes downregulated by S1P in 
HUVEC 126 111 
 
Table 3.5. Number of genes upregulated or downregulated by S1P in HUVEC that were also found 
to be either positively or negatively correlated with the expression of SPHK1 in primary DLBCL. 
 
  
Genes up regulated in 
HUVECs treated with 
S1P (n=93) 
Genes down regulated in 
HUVECs treated with S1P 
(n=111) 
Genes positively correlated with SPHK1 
expression in primary DLBCL (n=2145) 36 11 
Genes negatively  correlated with SPHK1 
expression in primary DLBCL (n=1537) 6 22 
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Table 3.6: Chi-square test of the overlap between genes correlated with the expression of SPHK1 
in primary DLBCL and those genes either upregulated or downregulated by S1P in HUVEC 
 
 
Observed 
(O) 
Expected 
(E) O-E 
Chi 
square 
Odds 
Ratio P-Value 
Genes positively correlated with 
SPHK1 expression in primary 
DLBCL and upregulated in S1P 
treated HUVEC 
36 11.43 24.57 52.78 4.55 p < 0.0001 
Genes negatively correlated 
with SPHK1 expression in 
primary DLBCL and upregulated 
in S1P treated HUVEC 
6 8.19 -2.19 0.59 0.71 0.442 
Genes positively correlated with 
SPHK1 expression in primary 
DLBCL and downregulated in 
S1P treated HUVEC 
11 13.65 -2.65 0.51 0.78 0.475 
Genes negatively correlated 
with SPHK1 expression in 
primary DLBCL and 
downregulated in S1P treated 
HUVEC 
22 9.78 12.22 15.27 2.58 p < 0.0001 
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Figure 3.18: The S1P-endothelial cell gene signature is present in primary DLBCL. Venn diagrams 
showing the overlap between genes positively or negatively correlated with SPHK1 in primary DLBCL 
(dark grey and blue circles respectively) with those genes upregulated or downregulated in S1P treated 
HUVEC (light grey and red circles respectively). Genes positively correlated with the expression of SPHK1 
in primary DLBCL were significantly enriched for genes upregulated, but not genes downregulated, by 
S1P in HUVEC (chi-square=52.78, odds ratio =4.55, p<0.0001; chi-square=0.51, odds ratio =0.78, p=0.48, 
respectively). It also revealed that genes negatively correlated with the expression of SPHK1 in primary 
DLBCL were significantly enriched for genes downregulated, but not genes upregulated, by S1P in HUVEC 
(chi-square=15.27, odds ratio =2.58, p<0.0001; chi-square=0.59, odds ratio =0.71, p=0.44). OR= odds 
ratio. 
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3.3 Discussion 
Most of the oncogenic effects of SPHK1 are a consequence of its ability to produce the 
bioactive signalling lipid S1P (Pyne, 2012, Pyne and Pyne, 2010, Maceyka et al., 2012). SPHK1 
is overexpressed in many cancer types such as kidney, lung, ovarian and pancreatic, and 
associated with an inferior survival in gastric, brain and breast cancer (French et al., 2003, 
Johnson et al., 2005, Guillermet-Guibert et al., 2009, Li et al., 2009, Van Brocklyn et al., 2005, 
Li et al., 2008b, Ruckhaberle et al., 2008). A previous study has documented the 
overexpression of SPHK1 in NHL. In this chapter I provide evidence that SPHK1 is 
overexpressed in the most common subtype of NHL, DLBCL (Bayerl et al., 2008). This was 
based on a reanalysis of two gene expression datasets which showed high levels of SPHK1 
mRNA in DLBCL compared with GC B cells. Although SPHK1 IHC showed strong staining in 
DLBCL tumour cells I could not reliably quantify this due to the lack of an internal positive 
control. Quantification of SPHK1 expression in tumour cells of DLBCL sections will require an 
alternative assay such as RNAscope, an RNA in-situ hybridisation technology (Wang et al., 
2012). At this time it is not technically feasible to measure S1P in tissue sections. Furthermore, 
the phospho-specific SPHK1 antibody used here is not specific in IHC. Therefore, I could only 
show that SPHK1 was constitutively phosphorylated in DLBCL lines.   
I showed that SPHK1 expression is associated with the expression of angiogenic genes in 
primary DLBCL. This could be important because overall survival has been shown to be 
significantly poorer for those DLBCL patients with tumours displaying high blood vessel density 
compared to those with low blood vessel density (54% versus 78%, respectively, p=0.004) 
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(Cardesa-Salzmann et al., 2011). For this reason SPHK1-S1P signalling could be a novel anti-
angiogenic target in DLBCL. 
As a first step to investigate the contribution of SPHK1 to DLBCL angiogenesis I used HUVEC to 
define an S1P-endothelial cell gene signature. Having shown that HUVEC recapitulated the S1P 
receptor expression observed in DLBCL-associated endothelial cells I then optimised 
conditions which enabled me to reliably activate ERK and downstream transcription.  
I showed that many of the transcriptional changes induced by the treatment of HUVEC with 
S1P were evident in SPHK1 expressing tumours, suggesting that S1P signalling is likely to be 
involved in DLBCL angiogenesis. This could be important because two studies have shown no 
association between microvessel density and VEGF expression in DLBCL (Gratzinger et al., 
2008, Jorgensen et al., 2007). This suggests that another pathway independent of VEGF 
signalling, potentially the SPHK1-S1P pathway, is driving blood vessel growth in these tumours. 
Further studies are required to determine if SPHK1 expression is associated with microvessel 
density in primary DLBCL. 
Although HUVEC proved useful in defining an S1P-endothelial cell gene signature, it should be 
noted that the S1P targets were defined following a single S1P stimulation which resulted in 
rapid and transient transcriptional changes. This almost certainly cannot completely 
recapitulate the in vivo steady state in which tumour-associated endothelial cells are likely to 
be chronically stimulated by S1P.   
The observation that the S1P-endothelial cell gene signature was significantly associated with 
SPHK1 expression in primary tumours was based on the analysis of gene expression datasets 
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generated from whole tumour biopsies. Therefore, any correlations observed cannot be 
attributed with certainty to a given cell type. Equally, this method may not be sensitive enough 
to determine genes expressed by the tumour endothelial cells, as the endothelial cells make 
up a low percentage of the total cell count in tumour biopsies. Therefore, the total gene 
expression level of any given gene in endothelial cells may be affected by its expression in 
other cell types. This problem could be overcome by gene expression analysis of endothelial 
cells isolated from primary DLBCL samples. 
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CHAPTER FOUR 
AN INVESTIGATION OF THE PHENOTYPIC EFFECTS OF 
THE S1P-ENDOTHELIAL CELL GENE SIGNATURE
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4.1 Abstract 
In the previous chapter I showed that genes co-expressed with SPHK1 in primary DLBCL are 
significantly enriched for angiogenic genes. Furthermore, I showed that S1P induces a gene 
expression programme in endothelial cells which is present in primary tumours. I hypothesise 
that in addition to increasing tumour angiogenesis, S1P might also induce other phenotypic 
effects on endothelial cells to promote tumour progression. 
In this chapter I explore the impact of S1P on the transcription of other genes in endothelial 
cells, including those not directly associated with angiogenesis.
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4.2 Results 
4.2.1 Gene ontology analysis reveals that the S1P-endothelial cell gene signature is enriched 
for angiogenic, anti-apoptotic and leukocyte extravasation and migration functions 
To explore the broader phenotypic effects of S1P signalling on endothelial cells, I initially 
performed a gene ontology analysis of the genes upregulated by S1P in HUVEC using an online 
functional classification tool, DAVID (https://david.ncifcrf.gov/) (Dennis et al., 2003). The 
significantly enriched gene ontology terms were grouped into functional categories and 
revealed a significant enrichment in angiogenic, anti-apoptotic, leukocyte extravasation and 
leukocyte chemotaxis functions (Figure 4.1).   
4.2.2 Genes upregulated by S1P in endothelial cells are involved in the recruitment of 
monocytes and granulocytes 
As the recruitment of stromal cells to the tumour microenvironment is increasingly recognised 
to play an important role in tumour progression, I chose to focus on the potential contribution 
of S1P-induced changes in the endothelial transcriptome to leukocyte recruitment (Lenz et al., 
2008b). 
The now firmly established process of leukocyte recruitment involves two main steps which 
have been extensively reviewed (reviewed in: Nourshargh and Alon, 2014, Hordijk, 2016, 
Vestweber, 2015, Muller, 2013). As part of the migration process, circulating leukocytes must 
first adhere to the endothelium. This association involves the expression of endothelial cell 
adhesion molecules. Secondly, the leukocytes are directed by chemoattractant gradients, 
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such as chemokines, to migrate across the endothelium (a process referred to as leukocyte 
extravasation) and into the tissue.  
I interrogated the S1P regulated genes in HUVEC for chemokines and adhesion molecules. This 
gave me 7 chemokines and 3 adhesion molecules (Table 4.1). I validated the upregulation of 
several of the chemokine genes in HUVEC following S1P treatment by qPCR. In addition to 
those previously validated (CXCL8 Figure 3.15; CCL2 Figure 3.17) I confirmed the upregulation 
of CCL7, CXCL1, CXCL3 and CXCL12 mRNA (Figure 4.2). The adhesion molecule genes involved 
in leukocyte extravasation ICAM1, SELE and VCAM1 had previously been validated (ICAM1 and 
SELE Figure 3.15; VCAM1 Figure 3.17). 
To further investigate the cell types that may be recruited by the chemokines and adhesion 
molecules regulated by S1P in HUVEC, I performed a PubMed search, 
(http://www.ncbi.nlm.nih.gov/pubmed), to identify the primary chemotactic/adhesion 
functions (Table 4.1). This literature search revealed that the chemokines and adhesion 
molecules regulated by S1P in HUVEC are primarily involved in the recruitment of monocytes 
and granulocytes.  
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Figure 4.1: Gene ontology analysis of S1P target genes in HUVEC. GO analysis of genes upregulated by 
S1P in HUVEC revealed enrichment of genes with anti-apoptosis, leukocyte extravasation, angiogenesis 
and cell migration/chemotaxis functions. Dark grey bars represent the observed percentage of 
upregulated genes in a particular GO category, and light grey bars represent the expected percentage 
of upregulated genes in a particular GO category. P value of each term was determined using Fisher’s 
exact test. 
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Table 4.1: A summary of the chemokines and endothelial cell adhesion molecules upregulated by S1P  
  
 Official 
Gene 
Symbol 
Official Gene 
Name 
Other Gene Names Primary Target 
Cell(s) 
Reported 
endothelial 
cell S1P 
target gene? 
(Yes/No) 
Significantly 
co-
expressed 
with SPHK1? 
(Yes/No)  
(p-value) 
C
h
e
m
o
ki
n
e
s 
CCL2 C-C motif 
chemokine 
ligand 2 
Monocyte 
chemotactic 
protein 1 (MCP-1) 
Monocytes 
(reviewed in: 
Deshmane et al., 
2009) 
Yes (Lin et 
al., 2007) 
No p= 0.23 
CCL7 C-C motif 
chemokine 
ligand 7 
Monocyte 
chemotactic 
protein 3 (MCP-3) 
Monocytes (Van 
Damme et al., 1992) 
No Yes p= 0.03 
CX3CL1 C-X3-C motif 
chemokine 
ligand 1 
Fractalkine Soluble: Monocytes, 
T Cells (Bazan et al., 
1997) 
 
Endothelial Cell 
Bound: Leukocyte 
Adhesion (Bazan et 
al., 1997) 
No No p= 0.054 
CXCL1 C-X-C motif 
chemokine 
ligand 1 
GRO1 oncogene, 
Neutrophil 
activating protein-1 
(NAP-3) 
Neutrophils (Moser 
et al., 1990) 
No Yes p= 0.027 
CXCL3 C-X-C motif 
chemokine 
ligand 3 
GRO3 oncogene, 
macrophage 
inflammatory 
protein-2-
beta (MIP2b) 
Granulocytes 
(Geiser et al., 1993) 
No No p= 0.076 
CXCL8 C-X-C motif 
chemokine 
ligand 8 
Interleukin8 (IL8) Granulocytes 
(Harada et al., 1994) 
Yes (Lin et 
al., 2007) 
Yes p= 0.005 
CXCL12 C-X-C motif 
chemokine 
ligand 12 
Stromal cell derived 
factor 1 (SDF1) 
Lymphocytes, 
endothelial 
progenitor cells: 
(Burger and Kipps, 
2006) 
No No p= 0.061 
A
d
h
e
si
o
n
 M
o
le
cu
le
s 
ICAM1 intercellular 
adhesion 
molecule 1 
CD54 Leukocytes 
(reviewed in: 
Etzioni, 1996) 
Yes 
(Shimamura 
et al., 2004) 
Yes p= 0.001 
SELE Selectin E E-selectin, CD62 Leukocytes 
(reviewed in:  
Etzioni, 1996) 
Yes (Xia et 
al., 1998) 
Yes p= 
0.0008 
VCAM1 vascular cell 
adhesion 
molecule 1 
CD106 lymphocytes, 
monocytes, 
eosinophils and 
basophils (reveiwed 
in: Etzioni, 1996) 
Yes (Xia et 
al., 1998) 
No p=0.177 
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Figure 4.2: Upregulation of chemokines by S1P treated HUVEC. qPCR analysis confirms the 
upregulation of CCL7 (A), CXCL1 (B), CXCL3 (C) and CXCL12 (D) in HUVEC treated with S1P for 4 hours 
(dark grey bars) relative to untreated cells (light grey bars) from four different donors (HUVEC 1-4). 
Samples were analysed in triplicate and are presented as 2
-ΔΔCT  
values in comparison to 
corresponding control.  
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4.2.3 Genes co-expressed with SPHK1 in primary DLBCL are enriched for a granulocyte and 
a tumour macrophage gene signature. 
Following tissue recruitment, monocytes are polarised by the local environment and 
differentiate into macrophages, a process controlled by many tissue specific factors (Richards 
et al., 2013, Gordon and Taylor, 2005). Before investigating if S1P-induced changes on the 
endothelial transcriptome are involved in the recruitment of monocytes and granulocytes, I 
first wanted to confirm that macrophages and granulocytes were present in the 
microenvironment of the SPHK1-expressing DLBCL I had identified earlier (Section 3.2.1). To 
do this, macrophages and granulocytes were counted in 4 hpf (high power fields) and 10 hpf, 
respectively (performed by pathologist Dr Maha Ibrahim) using CD68 and CD15 as markers 
(Reid et al., 2011, Wada et al., 2012). Cells within vessels or necrotic areas were excluded. The 
average number of cells per hpf is shown in Table 4.2. Representative IHC stains are shown in 
Figure 4.3. I detected both macrophages and granulocytes in all tumours (mean: 157.6, 8.9; 
median 177.3, 4.9; range 48.3-298.3, 0.8-212.1, respectively). There was no correlation 
between the numbers of macrophages and granulocytes in these tumours (Figure 4.4).
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Table 4.2: Average CD15 and CD68 counts from primary 
DLBCL cases. NA = not available 
 
DLBCL case 
number  
Average CD15 
Count (10 hpf) 
Average CD68 
Count (4 hpf) 
102 5.6 162.3 
196 4.3 NA 
204 0.8 NA 
95 4.1 118.5 
112 2.3 288.0 
134 6.9 175.8 
150 4.5 250.0 
154 4.9 48.3 
155 3.0 177.3 
159 4.0 125.0 
160 212.1 226.0 
161 8.1 250.3 
162 8.6 208.0 
166 11.2 186.8 
175 31.2 242.3 
176 3.0 240.8 
177 7.7 266.8 
189 7.0 132.8 
190 12.3 279.8 
191 1.0 114.3 
195 3.4 104.5 
197 9.4 208.5 
198 8.7 94.0 
200 5.8 176.0 
203 NA 298.3 
207 15.5 192.8 
208 1.5 183.3 
209 3.9 NA 
211 14.4 121.8 
212 41.5 122.0 
213 1.7 184.5 
214 16.1 131.8 
215 2.2 163.5 
220 1.7 99.0 
227 4.3 175.3 
231 3.2 237.5 
199 NA 125.3 
182 NA 201.8 
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Figure 4.3: Frequency of CD15+ granulocytes and CD68+ macrophages in DLBCL. DLBCL cases 
were stained for CD15 and CD68 by IHC. The average number of cells per high power field for 
CD15 and CD68 for each case is shown (A and C, respectively). Representative IHC stains from 
two cases for both CD15 and CD68 are shown (B and D, respectively). 
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Figure 4.4: Correlation between average CD15 and CD68 counts in primary DLBCL. This 
analysis reveals that there was no significant correlation between average CD15 and CD68 
counts. Pearson correlation, r=0.14, p=0.43.   
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As explained in Section 3.2.1, I could not accurately quantify the level of SPHK1 expression in 
these cases. However, to explore whether the presence of macrophages and granulocytes in 
the microenvironment of primary DLBCL is associated with the expression of SPHK1, I 
compared the genes significantly correlated with the expression of SPHK1 in primary DLBCL 
with published cell type specific gene signatures. I used a published tumour macrophage gene 
signature generated using a 3D network-based approach from a DLBCL gene expression 
dataset and shown to be conserved across multiple unrelated human cancer types (Doig et 
al., 2013). Using only genes present on both platforms, n= 17850 (Table 4.3), I compared the 
genes significantly correlated with SPHK1 expression with the tumour macrophage gene 
signature (Table 4.4). This analysis revealed that genes positively correlated with SPHK1 in 
primary DLBCL were significantly enriched for macrophage signature genes (chi-
square=264.66, odds ratio=9.99, p<0.0001; Table 4.5; Figure 4.5), whereas genes negatively 
correlated with SPHK1 in primary DLBCL were significantly depleted for macrophage signature 
genes (chi-square= 13.42, odds ratio=0, p=0.0002; Table 4.5; Figure 4.5). 
To confirm this observation, I used the re-analysis of a published RNAseq data set to show a 
significant positive correlation in the expression of SPHK1 and CD68 in primary DLBCL samples 
(n=86) (Figure 4.6). 
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Table 4.3. Number of genes positively and negatively correlated with SPHK1 expression in primary 
DLBCL, and present in the macrophage gene signature, including those used in the enrichment 
analyses. 
 
 
Total 
Number 
Number of genes used in enrichment analysis (present 
on both DLBCL-SPHK1 correlated genes dataset and 
macrophage signature dataset n=17850) 
Genes positively correlated with 
SPHK1 expression in primary DLBCL 2236 2150 
Genes negatively correlated with 
SPHK1 expression in primary DLBCL 1658 1517 
Macrophage gene signature 162 158 
 
Table 4.4. Number of genes in the macrophage signature that were also found to be either 
positively or negatively correlated with the expression of SPHK1 in primary DLBCL. 
 
 Macrophage gene signature (n=158) 
Genes positively correlated with SPHK1 expression in 
primary DLBCL (n=2150) 90 
Genes negatively  correlated with SPHK1 expression 
in primary DLBCL (n=1517) 0 
 
Table 4.5: Chi-square test of the overlap between genes correlated with the expression of SPHK1 
in primary DLBCL and those present in the macrophage gene signature. 
 
 
Observed 
(O) 
Expected 
(E) O-E Chi square 
Odds 
Ratio P-Value 
Macrophage gene signature 
and genes positively 
correlated with SPHK1 
expression in primary DLBCL 
90 19.03 70.97 264.66 9.99 <0.0001 
Macrophage gene signature 
and genes negatively 
correlated with SPHK1 
expression in primary DLBCL 
0 13.43 -13.43 13.42 0 0.0002 
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Figure 4.5: A macrophage gene signature is enriched in genes positively correlated with SPHK1 
expression in primary DLBCL. Venn diagrams showing the overlap between genes positively and 
negatively correlated with SPHK1 expression in primary DLBCL (dark grey and blue circles 
respectively) with a macrophage gene signature (light grey circles). Genes positively correlated with 
the expression of SPHK1 in primary DLBCL were significantly enriched for macrophage signature 
genes (chi-square=264.66, odds ratio =9.99, p<0.0001).  Genes negatively correlated with SPHK1 
expression in primary DLBCL were significantly depleted for macrophage signature genes (chi-
square=13.42, odds ratio =0.00, p=0.0002).  
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Figure 4.6: SPHK1 expression is correlated with the expression of CD68 in primary DLBCL. The 
reanalysis of RNAseq data shows a statistically significant correlation between SPHK1 expression 
and CD68 expression in 86 cases of primary DLBCL. Pearson correlation, r=0.60, p<0.0001. 
|121 
 
Next I used a published granulocyte gene signature generated from cDNA microarray analysis 
of purified subpopulations of peripheral blood cells (Palmer et al., 2006). Using only genes 
present on both platforms, n=10042 (Table 4.6), I compared the genes significantly correlated 
with SPHK1 expression with the genes present in the granulocyte gene signature (Table 4.7). 
This analysis revealed that genes positively correlated with SPHK1 in primary DLBCL were 
significantly enriched for the granulocyte signature genes (chi-square=49.02, odds ratio =2.6, 
p<0.0001; Table 4.8; Figure 4.7), whereas the genes negatively correlated with SPHK1 in 
primary DLBCL were significantly depleted for the granulocyte signature genes (chi-
square=12.02, odds ratio=3.3, p=0.0005; Table 4.8; Figure 4.7)  
To confirm this observation, I used the re-analysis of a published RNAseq data set to show a 
significant positive correlation in the expression of SPHK1 and CD15 in primary DLBCL samples 
(n=86) (Figure 4.8). 
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Table 4.6. Number of genes positively and negatively correlated with SPHK1 expression in primary 
DLBCL and present in the granulocyte gene signature including those used in the enrichment 
analyses. 
 
 
Total 
Number 
Number of genes used in enrichment analysis (present 
on both DLBCL-SPHK1 correlated genes dataset and 
granulocyte gene signature dataset n=10042) 
Genes positively correlated with 
SPHK1 expression in primary DLBCL 2236 1543 
Genes negatively correlated with 
SPHK1 expression in primary DLBCL 1658 1028 
Granulocyte gene signature 304 293 
 
Table 4.7. Number of genes in the granulocyte signature that were also found to be either 
positively or negatively correlated with the expression of SPHK1 in primary DLBCL. 
 
 Granulocyte gene signature (n=293) 
Genes positively correlated with SPHK1 expression 
in primary DLBCL (n=1543) 92 
Genes negatively  correlated with SPHK1 
expression in primary DLBCL (n=1028) 11 
 
Table 4.8: Chi-square test of the overlap between genes correlated with the expression of SPHK1 
in primary DLBCL and those present in the granulocyte gene signature. 
 
 
Observed 
(O) 
Expected 
(E) O-E 
Chi 
square 
Odds 
Ratio P-Value 
Granulocyte gene signature 
and genes positively 
correlated with SPHK1 
expression in primary DLBCL 
92 45.02 46.98 49.02 2.59 <0.0001 
Granulocyte gene signature 
and genes negatively 
Correlated with SPHK1 
expression in primary DLBCL 
11 29.99 -18.99 12.02 0.33 0.0005 
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Figure 4.7: A granulocyte gene signature is enriched in genes positively correlated with SPHK1 
expression in primary DLBCL. Venn diagrams showing the overlap between genes positively or 
negatively correlated with SPHK1 expression in primary DLBCL (dark grey and blue circles 
respectively) with a granulocyte gene signature (light grey circles). Genes positively correlated with 
the expression of SPHK1 in primary DLBCL were significantly enriched for granulocyte signature 
genes (chi-square=49.02, odds ratio =2.59, p<0.0001).  Genes negatively correlated with SPHK1 
expression in primary DLBCL were significantly depleted for the granulocyte signature genes (chi-
square=12.02, odds ratio =0.33, p=0.0005).  
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Figure 4.8: SPHK1 expression is correlated with the expression of CD15 in primary DLBCL. The 
reanalysis of RNAseq data shows a statistically significant correlation between SPHK1 expression 
and CD15 expression in 86 cases of primary DLBCL. Pearson correlation, r=0.34, p=0.001. 
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4.2.4 Investigating the S1P-induced chemotactic functions of endothelial cells in vitro 
The validation of chemokine secretion from HUVEC following treatment with S1P  
Having shown that S1P upregulates chemokines in HUVEC and that SPHK1 expression is 
enriched for macrophage and granulocyte gene signatures in primary DLBCL, I next explored 
the possibility that the chemokines upregulated by S1P in HUVEC recruit these cell types.   
For these set of experiments, I chose to focus on the chemokines which I showed to be 
positively correlated with SPHK1 expression in DLBCL. They included, CCL7, CXCL1 and CXCL8 
(Table 4.1). In the first instance I set out to confirm the upregulation and release of these 
chemokines from endothelial cells following S1P treatment. In vivo endothelial cells are 
exposed to S1P continually and having reflected on the S1P stimulation experiments (shown 
in Section 3.2.4) and the transient nature of the signal, I thought it might be possible to adjust 
the experimental conditions to better reflect what is seen in vivo. Two possible reasons for 
the transient nature of the ERK signal observed in vitro are that, S1PR1 surface expression is 
decreased following S1P exposure or alternatively that S1P is degraded in the cell media.  
I first investigated whether the transient ERK signal was due to loss of sensitivity to S1P by re-
challenging HUVEC with a second dose of S1P at 6 hours or 12 hours following the first. This 
analysis showed that those cells receiving a second stimulation activated ERK to the same level 
as control cells which had not received an initial stimulation (Figure 4.9), suggesting that cells 
remain sensitive to S1P after an initial stimulation 6 hours earlier. 
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Figure 4.9:  S1P treated HUVEC remain sensitive to restimulation with S1P. HUVEC were 
restimulated with S1P at 6 hours or 12 hours following an initial stimulation (A and B, respectively). 
Top panels show S1P stimulation times (red arrows) and the protein harvest times (green arrows) 
for each of the immunoblot samples, numbered by lane.  Immunoblotting revealed that cells 
receiving a second dose of S1P (lanes 4) activate ERK to the same level as cells which received no 
prior stimulation (lanes 1 and 2). β-tubulin confirmed equal loading of sample. Data shown are 
representative of three independent experiments from three different HUVEC donors. *=double 
dose S1P. 
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I next investigated if S1P in the cell medium is degraded overtime. I took conditioned media 
from HUVEC that had been treated with S1P for different times and used this to treat 
unstimulated HUVEC. I found that the medium of S1P treated HUVEC conditioned for > 8 hours 
was no longer capable of activating ERK (Figure 4.10). These data indicate that S1P is degraded 
in media overtime. In vitro re-stimulation of HUVEC requires fresh S1P.  
 I used an ELISA to measure CCL7, CXCL1 and IL8 in the conditioned media from S1P treated 
HUVEC. For these experiments, in addition to depleting the HUVEC of growth factors for 16 
hours prior to S1P stimulation, the medium was replaced again 1 hour prior to the initial S1P 
stimulation. I treated the HUVEC with one or two doses of S1P for up to 12h; the latter to 
potentially better mimic the effects seen in vivo. I chose the second dose time point of 6 hours, 
as I previously showed that HUVEC can re-activate ERK following a second stimulation 6h after 
the first (Figure 4.9). The conditioned medium was harvested 12 hours after the first S1P 
stimulation and subjected to ELISA analysis. Figure 4.11 shows that compared to controls, S1P 
induced a dose dependent increase in CXCL1 and IL8 levels in the cell supernatants. CCL7 levels 
were lower than the assay range standards and could therefore not be quantified.  
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Figure 4.10: S1P is degraded in culture overtime. Media from S1P and control treated HUVEC 
was conditioned for the indicated time periods. Unstimulated HUVEC were treated with the 
conditioned media for 5 minutes. Immunoblotting revealed that media conditioned from S1P 
treated HUVEC for > 8 h was no longer capable of activating ERK. β-tubulin confirmed equal 
loading of samples. Data shown are representative of two independent experiments from two 
different HUVEC donors. 
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Figure 4.11: ELISA analysis for the production of chemokines by S1P treated HUVEC. An ELISA was 
used to measure the levels of IL8 (A) and CXCL1 (B) in the conditioned media of HUVEC treated with 
S1P for 12 hours. Cells were either untreated (control) or treated with 1 dose of S1P at 0 hours or 2 
doses of S1P at 0h and 6h (1x S1P, 2x S1P, respectively). Analysis reveals the dose dependent 
upregulation of IL8 and CXCL1. Data are represented as mean ±SEM of three separate experiments. 
Students T-test. *p<0.05, **p<0.01. 
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Validation of monocyte migration to CXCL1: a chemokine secreted from HUVEC following 
treatment with S1P and co-expressed with SPHK1 in primary DLBCL  
CXCL1 and IL8, the two validated chemokines that I showed were upregulated by S1P in HUVEC 
and which were co-expressed with SPHK1 in primary DLBCL, are thought to act predominantly 
on neutrophils (Table 4.1). Therefore I chose to focus my studies on the recruitment of 
monocytes. IL8 has already been reported to recruit monocytes (Gerszten et al., 1999), 
therefore, I chose to investigate the ability of CXCL1 to recruit monocytes. 
To do this, I first wanted to establish an assay to measure the migration of monocytes to 
CXCL1. To do this I used the THP-1 human monocytic cell line which is derived from an acute 
monocytic leukaemia patient and is the most widely used monocyte cell line model. I exposed 
THP-1 cells to 50 ng/ml MCP1, one of the key chemokines that regulates migration of 
monocytes, in a transwell assay for 4 hours. Figure 4.12A shows a significant increase in THP-
1 cell migration to MCP-1 compared to controls, confirming that my migration assay works.  
Having optimised the THP-1 cell migration assay, I then tested the effects of CXCL1 on THP-1 
cell migration using the same conditions. This assay revealed a significant and dose dependent 
increase in THP-1 cell migration to CXCL1 (Figure 4.12B).    
Finally, I wanted to explore the effects of CXCL1 on the migration of primary human CD14+ 
monocytes as they are more representative of what is found in vivo. To do this I used CD14+ 
cells isolated from human peripheral blood (provided by Tracey Perry). Figure 4.13 shows that 
there was a significant increase in primary human CD14+ monocyte migration to MCP-1, 
however I observed no increase in primary human CD14+ monocytes to CXCL1 at 25 ng/ml or 
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50 ng/ml. Although this experiment indicates that primary human CD14+ monocyte migration 
do not migrate to CXCL1, repeated experiments from multiple donors would have to be 
performed for firm conclusions to be drawn, as donor variations in chemokine receptor 
expression have previously been described (Gerszten et al., 1999).  
|132 
 
 
 
Figure 4.12: Increased migration of THP-1 cells to MCP1 and CXCL1. (A) THP-1 cells were exposed 
to 50 ng/ml MCP1 in a transwell assay. After 4 hours, the cells that had migrated through the 
membrane were counted using a flow cytometer from triplicate wells. Analysis revealed a 
significant increase in THP-1 cell migration in the presence of MCP1 compared to controls. (B) THP-
1 cells were exposed to CXCL1 at the indicated concentration in a transwell assay. After 4 hours, 
the cells that had migrated through the membrane were counted using a flow cytometer from 
triplicate wells. Representative data are from one of four independent experiments. Analysis 
revealed the dose dependent migration of THP-1 cells to CXCL1. Student’s T-test; ***p<0.001, 
****p<0.0001. 
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Figure 4.13: Increased migration of human CD14+ monocytes to MCP1, but not CXCL1. Purified 
human CD14+ monocytes from blood were exposed to CXCL1 and MCP1 in a transwell assay at the 
indicated concentrations. After 4 hours, cells that had migrated through the membrane were 
counted using a flow cytometer from triplicate wells. Analysis reveals a significant increase in CD14+ 
monocyte migration in the presence of MCP1 and no difference in the presence of CXCL1.  Student’s 
T-test; ***p<0.001, n=1. 
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4.4 Discussion 
In this chapter I showed that genes upregulated by S1P in HUVEC are involved in the process 
of leukocyte recruitment. These genes include adhesion molecules and chemokines. In 
support of this finding, I showed that SPHK1 expression is correlated with the expression of a 
tumour macrophage gene signature and a granulocyte gene signature in primary DLBCL.  
Macrophages, which differentiate from monocytes, are the main cell type in the tumour 
microenvironment of DLBCL (Scott and Gascoyne, 2014). Tumour-associated macrophages 
(TAMs), most commonly macrophages of the M2 phenotype, can enhance tumour cell 
proliferation and invasion, increase angiogenesis, and inhibit the T cell-mediated anti-tumour 
immune response thereby promoting tumour progression (Qian and Pollard, 2010). Two 
studies have reported that high numbers of M2 macrophages (defined as CD68+CD163+ cells), 
but not M1 macrophages are associated with an adverse outcome in R-CHOP treated patients 
(Wada et al., 2012, Marchesi et al., 2015).  
Granulocytes have also been shown to be present in the DLBCL microenvironment and in one 
study were shown to express the B cell survival factor, APRIL (A Proliferating Inducing Ligand). 
In this study high expression of APRIL was associated with decreased overall patient survival 
(Schwaller et al., 2007). However, this study did not report the numbers of tumour infiltrating 
CD15+ cells. I observed very low numbers of infiltrating CD15+ cells in the microenvironment 
of DLBCL in the majority of cases, with an average of <10 cells per hpf. Even small numbers of 
cells producing soluble growth factors could be sufficient to promote DLBCL growth, but it 
would be of interest to determine if the numbers of infiltrating cells of the granulocytic lineage 
correlate with DLBCL survival. 
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It is not possible to determine from these analyses whether SPHK1 expression is responsible 
for the recruitment of monocytes/macrophages or granulocytes. Although the enrichment of 
macrophage and granulocyte gene signatures in the genes co-expressed with SPHK1 could be 
explained by other mechanisms, for example, the induction of SPHK1 expression on tumour 
cells by TAMs, two reports show that SPHK1-S1P signalling is responsible for macrophage 
recruitment in vivo. One of these studies showed that the inhibition of S1P signalling, by the 
S1P monoclonal antibody, Sphingomab, significantly reduced macrophage infiltration as well 
as neovascularisation in mice with oxygen induced ischemic retinopathy (Xie et al., 2009). In 
the second study, the numbers of macrophages were reduced in the livers and lungs of a 
mouse model of graft-versus-host disease (GVHD) in animals treated with an S1PR1 receptor-
selective antagonist CYM-5442, which induces S1PR1 internalisation, phosphorylation, and 
ubiquitination (Cheng et al., 2015). An in vivo model of DLBCL will be required to determine 
whether SPHK1 expression contributes to stromal cell recruitment in DLBCL. 
A previous study has shown that the expression of MCP1 and IL8 are upregulated following 
the treatment of HUVEC with S1P and that monocytes migrate towards conditioned media 
from S1P treated HUVEC (Lin et al., 2007). I have shown that S1P induces multiple chemokines 
in HUVEC, some of which may not be relevant to primary tumours. For this reason I focussed 
my initial experiments on those chemokines, IL8, CXCL1 and CCL7, upregulated by S1P in 
HUVEC and co-expressed with SPHK1 in primary DLBCL.  
Although I observed the upregulation of CCL7 mRNA following S1P treatment, a finding which 
is supported by the previous observation that CCL7 mRNA is downregulated in HUVEC treated 
with an S1PR1 inhibitor (CYM-5442) (Cheng et al., 2015), I could not detect CCL7 in the 
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conditioned media of S1P treated HUVEC. At the present time it is not clear if this is due to 
the low sensitivity of the ELISA kit used (standards gave low signal) or to post 
transcriptional/translational regulation of CCL7 expression. 
Although I was able to confirm the increased production of IL8 by HUVEC following S1P 
treatments, this chemokine has been shown to contribute to neutrophil and monocyte 
recruitment and I did not investigate its effects any further (Gerszten et al., 1999). I chose to 
focus on CXCL1 which is known to be involved in neutrophil, but not macrophage, recruitment. 
I optimised a migration assay using the THP-1 monocyte cell line and used this to show that 
CXCL1 promoted the migration of THP-1 cells. However, in one experiment I was unable to 
detect any change in migration of purified CD14+ monocytes to CXCL1. It has previously been 
shown that monocytes isolated from different donors vary in their migratory response to IL8 
an observation that might be explained by different levels of IL8 receptors, C-X-C motif 
chemokine receptor 1 and 2 (CXCR1 and CXCR2), on primary monocytes (Gerszten et al., 
1999). CXCR2 is the CXCL1 receptor. It remains to be seen if the failure of primary monocytes 
to migrate to CXCL1 in my experiment was due to low/absent expression of CXCR2 in these 
cells. Although my experiments mainly focused on migration it should be noted that both IL8 
and CXCL1 can also support monocyte arrest and firm adhesion onto endothelium under flow 
conditions (Smith et al., 2005, Gerszten et al., 1999). 
Tumour cells expressing chemokine receptors could be directed to the endothelial cell derived 
chemokines promoting intravasation of tumour cells from the primary site into the blood 
stream for dissemination and contributing to cancer metastasis. Adhesion molecules 
expressed on endothelial cells can facilitate the binding of tumour cells to the vasculature 
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(reviewed in: Kobayashi et al., 2007), for example E-selectin has been shown to regulate 
adhesion of a variety of cancer cell types, including lymphoma (Yoneda et al., 1994). In support 
of these studies, it has been shown that treatment with an SPHK1 inhibitor reduced 
metastases of a murine model of breast cancer to lymph nodes and lungs (Nagahashi et al., 
2012). Therefore, the S1P-induced upregulation of endothelial cell adhesion molecules and 
chemokines may contribute to DLBCL spread as well as leukocyte recruitment. 
In addition to angiogenesis and leukocyte recruitment, genes upregulated in HUVEC by S1P 
were also enriched for anti-apoptotic functions, these included BCL2 related protein A1 
(BCL2A1). The anti-apoptotic effects of S1P in endothelial cells has previously been described. 
For example, it has been shown that S1P protects HUVEC from serum starvation (Hisano et al., 
1999, Kwon et al., 2001). 
|138 
 
 
 
 
CHAPTER FIVE 
POTENTIAL THERAPEUTIC INHIBITION OF S1P-INDUCED 
ANGIOGENESIS AND STROMAL CELL RECRUITMENT IN 
DLBCL
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5.1 Abstract 
One third of patients with DLBCL have refractory disease or will relapse after current therapies 
and will eventually succumb to their disease. This highlights the necessity for the development 
of novel targeted therapies to treat DLBCL patients. In the preceding chapters I have shown 
that genes co-expressed with SPHK1 in primary DLBCL tumours are enriched for angiogenic 
gene signatures. In vitro I have provided evidence that in addition to the upregulation of 
angiogenic genes, the treatment of endothelial cells with S1P can mediate the increased 
secretion of chemokines known to be involved in monocyte and granulocyte migration. This 
is supported by the observation that macrophage and granulocyte gene signatures are 
enriched in genes co-expressed with SPHK1 in primary DLBCL. 
Therefore, inhibiting S1P signalling could not only target angiogenesis but also reduce stromal 
cell recruitment. To date, targeting S1P signalling has not been explored to treat angiogenesis 
in patients with primary DLBCL. In this part of the work I set out to test the ability of two 
available S1P signalling targeting drugs, Sphingomab and FTY720, to inhibit S1P-mediated 
angiogenesis and stromal cell recruitment. Sphingomab is an anti-S1P monoclonal antibody 
which sequesters S1P, preventing it from binding to its receptors. FTY720 is an analogue of 
sphingosine which binds to S1PR1, 3, 4 and 5. FTY720 binding induces S1PR1 internalisation 
and degradation resulting in prolonged receptor downregulation (Matloubian et al., 2004).   
 Here I first explore, using these inhibitors, the potential inhibition of S1P-induced activation 
of signalling pathways and gene expression changes in endothelial cells in vitro before 
validating a relevant murine model in which to test the potential therapeutic effects of S1P 
inhibition.
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5.2 Results 
5.2.1 Inhibition of S1P-induced ERK activation in HUVEC by Sphingomab and FTY720 
To test Sphingomab and FTY720 for their potential to inhibit S1P-mediated angiogenesis and 
stromal cell recruitment in DLBCL I first explored the ability of these drugs to inhibit S1P-
induced activation of ERK in HUVEC. To do this I treated HUVEC with Sphingomab at a range 
of concentrations. These experiments showed that Sphingomab blocked S1P-induced ERK 
activation in HUVEC at both 40 μg/ml and 75 μg/ml (Figure 5.1A). Importantly, the S1P-
induced ERK activation in HUVEC did occur in the presence of the same concentration of an 
isotype control antibody (Figure 5.1B). For all subsequent treatments I chose a concentration 
of 75 μg/ml of Sphingomab in the presence of 0.5 μM S1P to ensure efficient inhibition of S1P-
induced signalling. This concentration is similar to those previously used by other studies 
(O'Brien et al., 2009).  
Next, I explored the potential of FTY720 to inhibit the S1P-induced activation of ERK in HUVEC. 
I treated HUVEC with a range of concentrations of FTY720 for 1 hour prior to treatment with 
S1P. Figure 5.2 shows that 10 μM FTY720 blocked the S1P-induced activation of ERK. 
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Figure 5.1: Sphingomab inhibits S1P-induced ERK activation in HUVEC. (A) HUVEC were stimulated 
with S1P in the presence of increasing concentrations of Sphingomab (SmAb) and harvested at 5 
minutes. Immunoblotting revealed that compared to controls, Sphingomab blocked 0.5 μM S1P-
induced ERK activation in a dose dependent manner with total reversal of ERK activation in the 
presence of 40 ug/ml and 75 ug/ml of Sphingomab. β-tubulin confirmed equal loading of samples. 
(B) HUVEC were stimulated with S1P in the presence of 75 ug/ml Sphingomab (SmAb) or isotype 
control antibody (CmAb) and harvested at 5 minutes. Immunblotting revealed that the S1P-induced 
ERK activation was completely inhibited with Sphingomab but not with the isotype control 
antibody.  β-tubulin confirmed equal loading of samples. Data shown are representative of three 
independent experiments from three different HUVEC donors.       
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Figure 5.2: FTY720 inhibits S1P-induced ERK activation in HUVEC. HUVEC were pre-treated 
with increasing concentrations of FTY720 for 1 hour and then harvested following treatment 
with S1P for 5 minutes. Immunoblotting revealed that compared to control, FTY720 blocked 
S1P-induced ERK activation in a dose dependent manner with complete inhibition of ERK 
activation in the presence of 10 μM FTY720. 10 μM FTY720 treatment alone had no effect on 
ERK activation compared to control. β-tubulin confirmed equal loading of samples. Data shown 
are representative of three independent experiments from three different HUVEC donors.       
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5.2.2 Inhibition of S1P-induced gene upregulation in HUVEC 
Having shown that both Sphingomab and FTY720 can block the S1P-induced activation of ERK 
in HUVEC, I next wanted to explore if these drugs could also block the induction of S1P-induced 
gene expression in HUVEC. I performed qPCR on HUVEC treated with S1P for 4 hours in the 
presence of Sphingomab, FTY720 or controls. Figure 5.3 shows that Sphingomab inhibited the 
S1P-induced upregulation of ICAM1, SELE, CXCL1, and CXCL8 mRNA whereas the isotype 
control antibody did not. However, FTY720 treatment resulted in the upregulation of these 
genes (Figure 5.4). In subsequent experiments I focussed only on Sphingomab.  
5.2.3 Inhibition of S1P-induced chemokine release from HUVEC 
I next studied if the S1P-induced release of CXCL1 and IL8 from HUVEC could be inhibited in 
the presence of Sphingomab. Cells were treated with two doses of S1P in the presence of 
either Sphingomab or isotype control antibody. Conditioned media was harvested after 12 
hours and subjected to ELISA analysis.  Figure 5.5 shows that in the presence of Sphingomab 
the S1P-induced increase in CXCL1 and IL8 levels from HUVEC was inhibited.  By contrast, the 
isotype control antibody had no effect on the level of these chemokines following S1P 
treatment. 
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Figure 5.3: Sphingomab blocks the S1P-induced upregulation of adhesion molecules and 
chemokines in HUVEC. HUVEC were treated with S1P in the presence of Sphingomab (S mAb) or 
isotype control antibody (C mAb) for 4 hours. qPCR analysis shows that the S1P-induced 
upregulation of adhesion molecule genes ICAM1 (A) and SELE (B); and chemokine genes CXCL1 (C) 
and CXCL8 (D) was inhibited in the presence of Sphingomab, whereas isotype control antibody had 
no effect. Data shown are representative of three independent experiments from three different 
HUVEC donors. Samples were analysed in triplicate and are presented as 2
-ΔΔCT  
values in comparison 
to corresponding control.  
|145 
 
 
 
 
 
Figure 5.4:  FTY720 induces the upregulation of adhesion molecules and chemokines in HUVEC. 
HUVEC were pre-treated with FTY720 (FTY) for 1 hour prior to S1P treatment for an additional four 
hours. qPCR analysis shows that FTY720 treatment alone induced upregulation of ICAM1 (A), SELE 
(B), CXCL1 (C) and CXCL8 (D). Data shown are representative of three independent experiments from 
three different HUVEC donors. Samples were analysed in triplicate and are presented as 2
-ΔΔCT  
values 
in comparison to corresponding control.  
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Figure 5.5: Sphingomab inhibits the S1P-induced increase in chemokine levels in HUVEC. An ELISA 
was used to measure the levels of CXCL1 (A) and IL8 (B) in the conditioned media of HUVEC treated 
with S1P in the presence of Sphingomab (S mAb) or isotype control antibody (C mAb) for 12 hours. 
Analysis reveals the inhibition of S1P-induced increase in CXCL1 and IL8 levels in the presence of 
Sphingomab, but not in the presence of isotype control antibody. Data are represented as mean 
±SEM of four separate experiments. Students T-test.*** p<0.001. n/s = not significant.  
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5.2.4 In vitro studies for the validation of A20 BALB/c syngeneic model of DLBCL to test the 
potential therapeutic effects of SPHK1-S1P signalling targeting drugs 
A20 Cell Line Expresses SPHK1 
I chose to validate the A20 mouse model of lymphoma, in which immunocompetent BALB/c 
mice are injected with the A20 syngeneic B lymphoma cell line, to study the therapeutic effects 
of Sphingomab. This model has previously been used to study the microenvironment of DLBCL 
including the preclinical in vivo evaluation of immunotherapy against lymphoma (Briones et 
al., 2002, Siegel et al., 2003, Chaise et al., 2007, Serafini et al., 2008, Elpek et al., 2007). In the 
first instance I studied the expression of SPHK1 and its phosphorylation in the A20 cell line 
grown in vitro using immunoblotting. This suggests that A20 cells produce S1P like DLBCL 
primary tumours and is therefore a relevant cell model to study SPHK1-S1P signalling targeting 
drugs (Figure 5.6). 
S1P activates ERK in mouse endothelial cells 
For the next set of experiments I wanted to determine if S1P can also activate signalling in 
mouse endothelial cells. I was unable to successfully propagate mouse BALB/c endothelial 
cells in culture so I chose an extensively used murine endothelial cell line, sEnd-1 (Williams et 
al., 1989). I treated sEnd-1 cells with increasing concentrations of S1P and performed 
immunoblotting against pERK. Figure 5.7 reveals that sEnd-1 cells had a high basal level of 
pERK, attributed to the expression of polyoma middle T antigen, which mimics an activated 
growth receptor and activates many downstream signalling pathways (Schaffhausen and 
Roberts, 2009). A modest increase in pERK was detected by immunoblotting in those cells 
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treated with S1P. Due to this I performed densitometry to confirm the activation of ERK in 
those cells treated with S1P compared to control.  
S1P upregulates expression of adhesion molecules and chemokines in mouse endothelial 
cells 
Having shown that S1P activates ERK in mouse endothelial cells, I next wanted to determine 
if S1P can also upregulate adhesion molecules and chemokines in these cells. Mice do not 
express CXCL8, and CXCL1 is widely accepted as the functional homologue of CXCL8 in the 
mouse. I performed qPCR for ICAM1, SELE and CXCL1 on sEnd-1 cells treated with S1P for 4 
hours. Figure 5.8 shows that the expression of all three genes was upregulated following S1P 
treatment.
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Figure 5.6: A20 cells express SPHK1. Immunoblotting confirmed the expression of SPHK1 and its 
phosphorylation in the A20 cell line grown in vitro. β-tubulin confirmed equal loading of sample. 
Data shown are representative of three independent experiments  
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Figure 5.7: S1P activates ERK in sEnd-1 cells. sEnd-1 cells were treated with S1P at the indicated 
concentrations and harvested at 5 minutes. Immunoblotting reveals the S1P-induced activation of 
ERK compared to control cells. β-tubulin confirmed equal loading of sample. Data shown are 
representative of three independent experiments. Densitometry analysis of pERK expression is 
shown (bottom). Results were normalised by setting the densitometry of control cells to 1.0. Data 
shown are mean ±SEM of three separate experiments. Students T-test. *p<0.05, **p<0.01. 
|151 
 
 
Figure 5.8: S1P treatment of sEnd-1 cells is followed by the upregulation of ICAM1, SELE and 
CXCL1. sEnd-1 cells were treated with S1P at the indicated concentrations for 4 hours and subjected 
to qPCR analysis. This analysis reveals the upregulation of murine ICAM1 (A), SELE (B) and CXCL1 (C) 
genes. Samples were analysed in triplicate and are presented as 2
-ΔΔCT  
values in comparison to 
corresponding control.  
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5.2.5 In vivo studies for the validation of A20 BALB/c syngeneic model of DLBCL to test the 
potential therapeutic effects of SPHK1-S1P signalling targeting drugs 
A pilot study was performed to study the growth kinetics and engraftment of A20 cells injected 
intravenously into two BALB/c mice. A20 engrafted mice were culled at a humane endpoint 
(day 28). Post mortem revealed that animals had enlarged spleens and livers indicating 
engraftment of tumours in these organs (Figure 5.9A). Tumour load was measured by weight 
of engrafted organs compared to organs from control animals (Figure 5.9B). H&E staining 
confirmed the engraftment of tumour cells in the spleens and livers which revealed multiple 
foci of rounded aggregates of tumour cells distributed throughout both organs (Figure 5.9C).  
IHC was performed on sections from the A20 engrafted livers and spleens. A20 engrafted 
tumour cells were positive for SPHK1 in both the spleen and liver (Figure 5.8). Additionally 
tumours contained CD31+ endothelial cells, CD15+ granulocytes and CD68+ macrophages 
(Figure 5.10).
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Figure 5.9. A20 lymphoma cell infiltration of mouse spleen and liver following intravenous 
injection. Two BALB/c mice were injected intravenously with A20 tumour cells (A20 IV-1 and A20 
IV-2) and sacrificed after 28 days. Post mortem revealed enlarged spleens and livers in the A20 IV 
animals compared to corresponding organs from a control mouse (A, left and right panels, 
respectively). Spleen and liver weights of A20 IV animals was increased compared to control (B, left 
and right panels, respectively). H&E IHC sections confirmed the engraftment of A20 tumour cells 
(black arrows) in the spleen and liver (C, left and right panels, respectively).  
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Figure 5.10: A20 tumours express SPHK1 and recruit stromal cell components in vivo. IHC analysis of 
sections from A20 engrafted spleen and liver (left and right panels, respectively) revealed A20 tumour 
cell expression of SPHK1, infiltration of tumour cells with endothelial cells (H&E black arrows and CD31), 
granulocytes (CD15) and macrophages (CD68).  
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5.3 Discussion 
In this chapter I have shown that I can inhibit S1P-induced gene expression in HUVEC. I also 
demonstrated that the A20 syngeneic B-cell lymphoma mouse model can be used to study the 
therapeutic targeting of SPHK1-S1P signalling.  
Sphingomab, a monoclonal antibody against S1P, blocked the S1P-induced activation of ERK, 
the upregulation of S1P targets and chemokine release in HUVEC. This supports in vivo studies 
which have shown that in the presence of Sphinomab, microvessel density was reduced in 
lung and ovarian tumour mouse models (Visentin et al., 2006). Previous studies have also 
shown that Sphingomab can significantly reduce macrophage infiltration and vascularisation 
in mice with oxygen induced ischemic retinopathy (Xie et al., 2009). Taken together, these 
observations could support the future testing of Sphingomab in preclinical models of DLBCL. 
In contrast, treatment of HUVEC with FTY720 induced the upregulation of S1P target genes. 
FTY720 is an S1P receptor agonist, however these effects are followed by the prolonged 
downregulation of S1PR1 from the cell surface. It is possible that the upregulation of S1P 
target genes which I observed reflects the initial agonistic function of FTY720. It would be 
important to explore the effects of FTY720 on S1P-mediated upregulation of genes at a time 
point later than 4 hours. The inhibitory effects of FTY720 on S1P-mediated angiogenesis has 
been demonstrated in melanoma, lung and hepatocellular carcinoma mouse xenograft 
models, which showed reduction in blood vessel density following treatment with FTY720 
(Schmid et al., 2005, LaMontagne et al., 2006, Ho et al., 2005).  
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The potential therapeutic effects of S1P signalling inhibitors on tumour angiogenesis and 
stromal cell recruitment have not been explored in a preclinical model of DLBCL. I have shown 
here that the A20 syngeneic model of DLBCL could be used to assess the efficacy of SPHK1-
S1P targeting compounds in vivo. Furthermore I have shown using the sEnd-1 cell line that S1P 
can induce adhesion molecules and chemokines expression in mouse endothelial cells, albeit 
to a lesser extent than I observed in HUVEC. At the time of writing, experiments are underway 
to investigate if the S1P neutralising antibody, Sphingomab, can inhibit S1P target gene 
expression in the endothelial cells of A20 tumours. Furthermore it is important to note that 
differences exist in chemokine expression between the human and mouse. For example, IL8 
is expressed in humans but not in the mouse.  
A20 tumours displayed evidence of recruitment of macrophages, granulocytes and 
endothelial cells, further confirming the utility of this model to explore the effects of S1P on 
these stromal cells. To identify macrophages and granulocytes I used well established 
antibodies to detect CD68 and CD15 directed against human proteins. In preliminary 
experiments I showed that mouse cells with a morphology characteristic of macrophages and 
granulocytes were strongly stained with the anti-human CD68 and CD15, respectively.  In 
future studies I plan to use reagents directed against mouse markers, for example, F4/80 
which is expressed on most tissue macrophages in the mouse. Future work could also include 
the identification of the M1 and M2 phenotype of macrophages to assess the potential 
changes in the ratio of these macrophage types following treatment with SPHK-S1P targeting 
agents. Furthermore, the characterisation of the granulocytic cells infiltrating the tumour 
could be performed such as the identification of neutrophils by expression of Ly6G. 
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The multiplexed IHC technology analysed on multiplex biomarker imaging systems, such as 
the OPAL staining analysed on the Vectra quantitative imaging system (both; PerkinElmer Inc. 
Seer Green, United Kingdom), could be considered. In addition to a more sensitive and 
accurate analysis of the infiltrating stromal cells, this would allow for multiplex staining, which 
could include F4/80 and MHC class II staining to identify M1 macrophages and F4/80 and 
CD206 and/or CD163 to identify M2 macrophages.
|158 
 
 
 
 
CHAPTER SIX 
CONCLUSIONS AND FUTURE PERSPECTIVES
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DLBCL is a highly heterogeneous disease both molecularly and clinically. However, most 
patients are treated with the R-CHOP regimen. Although the addition of rituximab to CHOP 
saw great improvements in the survival of DLBCL patients, one-third of patients still relapse 
or have refractory disease and 5 year overall survival is only 60% (HMRN, 2016). Novel 
therapies that target components of the tumour microenvironment are being developed that 
might provide better, less toxic treatments. 
 In this thesis I have focussed on the potential contribution of S1P signalling to the phenotype 
of the tumour microenvironment. My data show that expression of SPHK1, the major enzyme 
that produces S1P, is associated with the expression of angiogenic genes in DLBCL. 
Furthermore, my studies also showed that many of the transcriptional changes induced by the 
treatment of endothelial cells with S1P in vitro were evident in SPHK1-expressing tumours, 
suggesting that tumour-derived S1P is likely to be involved in tumour angiogenesis in DLBCL.  
Clinical trials of angiogenesis inhibitors have so far produced disappointing results. However 
this may have been because some tumours show less evidence of an angiogenic phenotype 
and therefore might be less susceptible to anti-angiogenic drugs. Alternatively, the angiogenic 
phenotype may be driven by another signalling pathway to VEGF, such as SPHK1-S1P. 
Stratification of patients up front before therapy should be considered before anti-angiogenic 
treatments. In this regard it is noteworthy that a phase two clinical trials of Sphingomab in 
renal cell carcinoma patients was terminated as the overall median time to progression was 
less than two months in 39 patients. However, this clinical trial did not stratify patients to 
identify which would benefit from Sphingomab treatment. Seven patients were progression 
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free for at least six months and three of which were for over 20 months. Six patients still 
received treatment at the date of the report (PRnewswire, 2015) 
To identify patients who might benefit from SPHK1-S1P signalling targeting therapies, future 
studies could identify or develop useful biomarkers which would enable stratification of 
patients. Considerations could be to identify those patients with tumours which express high 
levels of SPHK1 and/or tumours with high microvessel density, both of which could be 
identified from tumour biopsies. Another possibility could be the development of a test to 
identify whether serum S1P levels are a useful biomarker. Furthermore, with the ever 
advancing technology in the field of diagnostics,  the presence of an S1P signalling expression 
profile, determined by gene expression profiling of patient samples, could be used to identify 
those patients which would potentially benefit from SPHK1-S1P signalling targeting agents. 
As well as having direct effects on the expression of angiogenesis-associated genes in 
endothelial cells, my data also point to important contributions of S1P-induced endothelial 
cell-derived chemokines, to the pathogenesis of DLBCL. My preliminary studies and the work 
of other groups suggest that the induction of these chemokines by S1P is likely to be important 
for endothelial cell mediated recruitment of stromal cells including monocytes/macrophages 
and granulocytes, to DLBCL. These cell types are known to contribute to tumour cell survival 
and immune escape (Qian and Pollard, 2010, Schwaller et al., 2007).  
I was able to block S1P-induced ERK activation and gene expression changes in HUVEC, 
suggesting that drugs such as Sphingomab might reverse S1P-induced tumour angiogenesis 
and endothelial cell mediated stromal cell recruitment. In addition to Sphingomab, further 
work could also include FTY720. FTY720, which has also been shown to be an effective agent 
|161 
 
in many types of cancer in animal models, is already being used clinically for the treatment of 
multiple sclerosis (Brinkmann et al., 2010, Kappos et al., 2006). Focussing on an agent which 
is already FDA approved, could mean getting FTY720 into DLBCL treatment regimens faster.   
Pre-clinical studies on the feasibility of using SPHK1-S1P targeting compounds to treat DLBCL 
are necessary before clinical trials can be considered. I have shown that the A20 syngeneic 
model of DLBCL would seem to be a relevant model with which to assess the efficacy of SPHK1-
S1P targeting compounds in vivo. It would be especially desirable to study the effects of 
inhibiting SPHK-S1P signalling using either humanised mouse models with human B cell 
lymphoma cells implanted, or patient derived xenografts (PDX) models. PDX models, which 
are based on the transfer of primary tumours directly from the patient into an 
immunodeficient mouse, are reported to maintain more similarities to the parental tumour 
such as histology and gene expression profiling (Siolas and Hannon, 2013).  
Although some way off a clinical trial, it is worth considering where in the care pathway drugs 
that target SPHK1-S1P signalling might be positioned. It seems likely that in the first instance 
they will be tested in patients treated unsuccessfully with front-line and salvage therapies. If 
successful in this scenario then trials with and without these new drugs in combination with 
R-CHOP could be considered. 
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APPENDICES 
Appendix 1: SPHK1 and S1P receptor IHC staining results of primary DLBCL cases 
+ = positive, - = negative, NA = not available, yellow shading = no internal positive control. 
Case 
Number  
SPHK1 
Tumour 
expression 
S1PR1 
Endothelial 
cell 
expression 
S1PR2 
Endothelial 
cell 
expression 
S1PR3 
Endothelial 
cell 
expression 
95 +  +  -   - 
102  -  +  -   -  
112 +  +  -   - 
134 +  +  -   - 
138 CRUSHED CRUSHED  CRUSHED   CRUSHED 
150 +  +  -   - 
154 +  +  -   -  
155 +  +  -   - 
159 +  +  -   - 
160 +  +  -   -  
161 +  +  -   -  
162 +  +  -   - 
166 +  +  -   -  
175 +  +  -   - 
176 +  +  -   -  
177 +  +  -   - 
182 +  +  -  NA 
189 +  +  -   - 
190 +  +  -   - 
191 +  +  -   - 
195 +  + NA  - 
196 -  +  -   - 
197 + NA  -   -  
198 +  +  -   - 
199 + NA  -  NA 
200 +  +  -  - 
203 +  + NA  -  
204 +  +  -   - 
207 +  +  -   - 
208 +  +  -   -  
209 +  +  -   -  
211 +  +  -   -  
212 +  +  -   -  
213 +  +  -   -  
214 +  + NA  -  
215 +  +  -   -  
220 +  +  -   -  
227 +  +  -   - 
231 +  +  -  -  
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Appendix 2: Genes regulated by S1P in HUVEC 
Genes downregulated by S1P in HUVEC Genes upregulated by S1P in HUVEC 
Gene Symbol Fold Change P-Value Gene Symbol Fold Change P-Value 
NELL2 -3.18 0.010 CSF2 3.39 1.87E-07 
ZNF888 -2.80 0.000 BCL2A1 3.37 7.38E-05 
CSNK1E -2.70 0.000 CSF3 3.34 3.66E-07 
CMPK2 -2.65 0.039 NBPF25P 3.00 0.026 
NEU3 -2.54 0.030 CCL7 2.80 0.001 
TBC1D3P1-DHX40P1 -2.45 0.028 TRAF1 2.48 0.000 
GPRASP1 -2.42 0.001 MORN3 2.43 0.002 
LOC441155 -2.39 0.046 COL1A1 2.29 0.001 
CEP170P1 -2.36 0.037 KCNN2 2.22 0.027 
FLRT3 -2.28 0.001 CX3CL1 2.20 0.002 
CCNE2 -2.20 0.003 PXN-AS1 2.18 0.004 
ZNF808 -2.19 0.003 CXCL3 2.14 0.000 
PLCL1 -2.17 0.027 MRS2P2 2.14 0.002 
CRYBG3 -2.15 0.030 SELE 2.08 0.002 
MKRN9P -2.08 0.014 CYSRT1 2.03 0.042 
HIST2H2BE -2.06 0.004 PTPN7 2.00 0.003 
SERPINI1 -2.05 0.016 PWARSN 1.99 0.003 
ULBP3 -1.96 0.040 LOC100506076 1.96 0.009 
CEP152 -1.96 0.000 S100A3 1.96 0.031 
GALNT15 -1.94 0.021 RRAD 1.94 0.001 
ZNF680 -1.92 0.013 CCNI2 1.93 0.016 
DOCK3 -1.92 0.049 C19orf18 1.93 0.022 
FOXF1 -1.92 0.028 ZP3 1.91 0.020 
FAM156A -1.92 0.028 LTB 1.89 0.026 
NHS -1.89 0.034 POU2F2 1.83 0.008 
FSTL5 -1.87 0.001 CD83 1.82 0.006 
MANEA -1.87 0.002 BIRC3 1.81 0.001 
ZNF488 -1.87 0.017 VSIG2 1.80 0.007 
ZNF549 -1.84 0.047 UFSP1 1.79 0.035 
CNTN1 -1.83 0.022 RASSF8-AS1 1.78 0.033 
CYP26B1 -1.83 0.011 VCAM1 1.77 0.022 
RAB43 -1.83 0.017 PDE8B 1.77 0.022 
DNAJB4 -1.78 0.043 MIR17HG 1.76 0.012 
PYGO1 -1.78 0.022 LOC101929709 1.75 0.007 
RFXAP -1.77 0.002 EIF4EBP3 1.75 0.035 
E2F8 -1.77 0.021 ANKHD1-EIF4EBP3 1.74 0.012 
SENP7 -1.77 0.044 LOC100128398 1.74 0.012 
SATB2 -1.76 0.042 LOC286437 1.73 0.037 
PFKFB2 -1.76 0.045 MEI1 1.73 0.025 
|164 
 
HSPA4L -1.75 0.014 MT1X 1.72 0.023 
CYB5R4 -1.74 0.007 LOC101926963 1.72 0.007 
PKNOX2 -1.72 0.017 MYEOV 1.71 0.028 
ZNF92 -1.71 0.011 LOC100131564 1.71 0.007 
PCGF6 -1.71 0.027 PSORS1C1 1.70 0.026 
DDX60 -1.70 0.023 ADM2 1.70 0.027 
CMTR2 -1.69 0.034 ANG 1.68 0.010 
KIAA1109 -1.69 0.002 HIST1H2BD 1.67 0.015 
FREM3 -1.69 0.048 RND1 1.67 0.008 
IGFBP5 -1.68 0.022 TNFAIP2 1.65 0.001 
RECQL -1.68 0.029 PRSS53 1.64 0.009 
APC -1.65 0.001 CXCL12 1.64 0.041 
UPRT -1.64 0.005 RELB 1.64 0.002 
RNFT1 -1.64 0.033 MYADM 1.64 0.001 
TSPAN12 -1.62 0.022 MFI2-AS1 1.63 0.017 
UBE2V1 -1.61 0.043 RNF207 1.63 0.043 
GRAMD1C -1.61 0.032 TFPT 1.62 0.046 
SESN3 -1.60 0.023 KANSL1-AS1 1.60 0.028 
USP53 -1.60 0.014 ARL17A 1.59 0.047 
CFAP44 -1.59 0.013 SPHK1 1.59 0.013 
CEP128 -1.59 0.010 PPM1J 1.59 0.025 
C1orf226 -1.58 0.023 ICOSLG 1.58 0.004 
CHML -1.58 0.017 ANKRD18B 1.58 0.021 
ARHGAP28 -1.58 0.009 LOC102724434 1.57 0.038 
REV3L -1.58 0.028 ICAM1 1.57 0.005 
WNK3 -1.58 0.044 SPOCD1 1.57 0.011 
TEF -1.58 0.027 ISG20 1.56 0.036 
LOC727896 -1.57 0.029 LRP2BP 1.56 0.019 
KIF14 -1.57 0.019 ZBED3 1.56 0.010 
ZBTB41 -1.56 0.032 C11orf80 1.55 0.014 
SNX16 -1.55 0.021 DNAH5 1.55 0.044 
ZSCAN31 -1.55 0.050 IFI27L1 1.54 0.028 
TFEC -1.54 0.019 PET100 1.54 0.024 
CNTRL -1.54 0.013 C8orf76 1.54 0.048 
ZNF644 -1.54 0.029 C2CD4B 1.53 0.020 
PDIK1L -1.54 0.037 LINC00152 1.53 0.037 
EGR1 -1.53 0.030 PIN1P1 1.53 0.042 
FAM117B -1.53 0.029 PRNCR1 1.51 0.011 
ZNF112 -1.52 0.017 C11orf91 1.50 0.034 
ZNF765 -1.52 0.023 DNPH1 1.50 0.049 
ZNF215 -1.52 0.041 MAP1B 1.49 0.033 
ETNK1 -1.51 0.022 SDC4 1.49 0.002 
XRN1 -1.51 0.047 STAG3L1 1.49 0.039 
ZNF678 -1.51 0.034 GATA2-AS1 1.48 0.017 
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ZDHHC17 -1.50 0.044 CASC10 1.48 0.031 
INCA1 -1.50 0.049 NFKB2 1.48 0.009 
RNF182 -1.50 0.046 POLR2J3 1.48 0.049 
USP32P1 -1.50 0.050 DHRS4L2 1.48 0.044 
MIS18BP1 -1.49 0.026 FTH1P3 1.48 0.039 
GJA5 -1.49 0.049 MSX1 1.47 0.043 
AHCTF1P1 -1.48 0.031 TRIM47 1.46 0.015 
TMEM79 -1.48 0.047 SOX4 1.43 0.035 
SEMA6A -1.47 0.032 CCL2 1.43 0.011 
TBK1 -1.47 0.008 DAPK3 1.43 0.031 
LACTB2 -1.47 0.038 UPP1 1.43 0.045 
ZNF100 -1.47 0.045 MIR155HG 1.42 0.042 
USP45 -1.47 0.043 FGGY 1.41 0.037 
ZNF117 -1.47 0.041 LINC-PINT 1.41 0.036 
TTK -1.46 0.014 CEBPD 1.40 0.027 
CDKN2C -1.46 0.018 ANGPTL4 1.40 0.025 
NRROS -1.45 0.016 HLX 1.40 0.033 
ZCCHC11 -1.45 0.029 C10orf54 1.39 0.026 
TOP1P1 -1.45 0.043 GFPT2 1.39 0.031 
KIAA1551 -1.45 0.028 RASAL3 1.39 0.050 
TRMT1L -1.45 0.027 FSTL3 1.38 0.032 
HLTF -1.44 0.035 PDGFA 1.38 0.019 
MAF -1.44 0.039 MED18 1.37 0.043 
DLL4 -1.44 0.029 PLAUR 1.37 0.022 
EVI2B -1.43 0.049 TMEM217 1.37 0.025 
DNAJB14 -1.43 0.031 KLF6 1.35 0.023 
RANBP2 -1.43 0.025 PHF20 1.35 0.023 
FERMT1 -1.43 0.042 RSPO3 1.33 0.035 
IFT80 -1.43 0.040 COL27A1 1.33 0.038 
ATG4C -1.42 0.044 ITSN2 1.32 0.038 
GMFB -1.42 0.022 CALD1 1.30 0.037 
DDX26B -1.41 0.042 CXCL1 1.30 0.041 
TBC1D31 -1.41 0.045 RUNX1T1 1.30 0.018 
FAR1 -1.41 0.016    
TTC37 -1.41 0.028    
LRRC40 -1.40 0.039    
BRWD3 -1.40 0.033    
USO1 -1.40 0.037    
MPHOSPH9 -1.39 0.032    
SMCHD1 -1.39 0.043    
MSH2 -1.38 0.031    
STAG2 -1.38 0.030    
CRY2 -1.35 0.034    
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